var title_f8_24_8576="Predicted body weight and tidal volume for women";
var content_f8_24_8576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Predicted body weight and tidal volume for women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Height",
"       </td>",
"       <td class=\"subtitle1\">",
"        PBW",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Tidal volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Feet/inches",
"       </td>",
"       <td class=\"subtitle2\">",
"        Inches",
"       </td>",
"       <td class=\"subtitle2\">",
"        Centimeters",
"       </td>",
"       <td class=\"subtitle2\">",
"        Kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        4 mL/kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        5 mL/kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        6 mL/kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        7 mL/kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        8 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 0\"",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"       <td class=\"centered\">",
"        122",
"       </td>",
"       <td class=\"centered\">",
"        17.9",
"       </td>",
"       <td class=\"centered\">",
"        72",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        107",
"       </td>",
"       <td class=\"centered\">",
"        125",
"       </td>",
"       <td class=\"centered\">",
"        143",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 1\"",
"       </td>",
"       <td class=\"centered\">",
"        49",
"       </td>",
"       <td class=\"centered\">",
"        124",
"       </td>",
"       <td class=\"centered\">",
"        20.2",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        101",
"       </td>",
"       <td class=\"centered\">",
"        121",
"       </td>",
"       <td class=\"centered\">",
"        141",
"       </td>",
"       <td class=\"centered\">",
"        162",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 2\"",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        127",
"       </td>",
"       <td class=\"centered\">",
"        22.5",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"       <td class=\"centered\">",
"        113",
"       </td>",
"       <td class=\"centered\">",
"        135",
"       </td>",
"       <td class=\"centered\">",
"        158",
"       </td>",
"       <td class=\"centered\">",
"        180",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 3\"",
"       </td>",
"       <td class=\"centered\">",
"        51",
"       </td>",
"       <td class=\"centered\">",
"        130",
"       </td>",
"       <td class=\"centered\">",
"        24.8",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        124",
"       </td>",
"       <td class=\"centered\">",
"        149",
"       </td>",
"       <td class=\"centered\">",
"        174",
"       </td>",
"       <td class=\"centered\">",
"        198",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 4\"",
"       </td>",
"       <td class=\"centered\">",
"        52",
"       </td>",
"       <td class=\"centered\">",
"        132",
"       </td>",
"       <td class=\"centered\">",
"        27.1",
"       </td>",
"       <td class=\"centered\">",
"        108",
"       </td>",
"       <td class=\"centered\">",
"        136",
"       </td>",
"       <td class=\"centered\">",
"        163",
"       </td>",
"       <td class=\"centered\">",
"        190",
"       </td>",
"       <td class=\"centered\">",
"        217",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 5\"",
"       </td>",
"       <td class=\"centered\">",
"        53",
"       </td>",
"       <td class=\"centered\">",
"        135",
"       </td>",
"       <td class=\"centered\">",
"        29.4",
"       </td>",
"       <td class=\"centered\">",
"        118",
"       </td>",
"       <td class=\"centered\">",
"        147",
"       </td>",
"       <td class=\"centered\">",
"        176",
"       </td>",
"       <td class=\"centered\">",
"        206",
"       </td>",
"       <td class=\"centered\">",
"        235",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 6\"",
"       </td>",
"       <td class=\"centered\">",
"        54",
"       </td>",
"       <td class=\"centered\">",
"        137",
"       </td>",
"       <td class=\"centered\">",
"        31.7",
"       </td>",
"       <td class=\"centered\">",
"        127",
"       </td>",
"       <td class=\"centered\">",
"        159",
"       </td>",
"       <td class=\"centered\">",
"        190",
"       </td>",
"       <td class=\"centered\">",
"        222",
"       </td>",
"       <td class=\"centered\">",
"        254",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 7\"",
"       </td>",
"       <td class=\"centered\">",
"        55",
"       </td>",
"       <td class=\"centered\">",
"        140",
"       </td>",
"       <td class=\"centered\">",
"        34",
"       </td>",
"       <td class=\"centered\">",
"        136",
"       </td>",
"       <td class=\"centered\">",
"        170",
"       </td>",
"       <td class=\"centered\">",
"        204",
"       </td>",
"       <td class=\"centered\">",
"        238",
"       </td>",
"       <td class=\"centered\">",
"        272",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 8\"",
"       </td>",
"       <td class=\"centered\">",
"        56",
"       </td>",
"       <td class=\"centered\">",
"        142",
"       </td>",
"       <td class=\"centered\">",
"        36.3",
"       </td>",
"       <td class=\"centered\">",
"        145",
"       </td>",
"       <td class=\"centered\">",
"        182",
"       </td>",
"       <td class=\"centered\">",
"        218",
"       </td>",
"       <td class=\"centered\">",
"        254",
"       </td>",
"       <td class=\"centered\">",
"        290",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 9\"",
"       </td>",
"       <td class=\"centered\">",
"        57",
"       </td>",
"       <td class=\"centered\">",
"        145",
"       </td>",
"       <td class=\"centered\">",
"        38.6",
"       </td>",
"       <td class=\"centered\">",
"        154",
"       </td>",
"       <td class=\"centered\">",
"        193",
"       </td>",
"       <td class=\"centered\">",
"        232",
"       </td>",
"       <td class=\"centered\">",
"        270",
"       </td>",
"       <td class=\"centered\">",
"        309",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 10\"",
"       </td>",
"       <td class=\"centered\">",
"        58",
"       </td>",
"       <td class=\"centered\">",
"        147",
"       </td>",
"       <td class=\"centered\">",
"        40.9",
"       </td>",
"       <td class=\"centered\">",
"        164",
"       </td>",
"       <td class=\"centered\">",
"        205",
"       </td>",
"       <td class=\"centered\">",
"        245",
"       </td>",
"       <td class=\"centered\">",
"        286",
"       </td>",
"       <td class=\"centered\">",
"        327",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4' 11\"",
"       </td>",
"       <td class=\"centered\">",
"        59",
"       </td>",
"       <td class=\"centered\">",
"        150",
"       </td>",
"       <td class=\"centered\">",
"        43.2",
"       </td>",
"       <td class=\"centered\">",
"        173",
"       </td>",
"       <td class=\"centered\">",
"        216",
"       </td>",
"       <td class=\"centered\">",
"        259",
"       </td>",
"       <td class=\"centered\">",
"        302",
"       </td>",
"       <td class=\"centered\">",
"        346",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 0\"",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        152",
"       </td>",
"       <td class=\"centered\">",
"        45.5",
"       </td>",
"       <td class=\"centered\">",
"        182",
"       </td>",
"       <td class=\"centered\">",
"        228",
"       </td>",
"       <td class=\"centered\">",
"        273",
"       </td>",
"       <td class=\"centered\">",
"        319",
"       </td>",
"       <td class=\"centered\">",
"        364",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 1\"",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"       <td class=\"centered\">",
"        155",
"       </td>",
"       <td class=\"centered\">",
"        47.8",
"       </td>",
"       <td class=\"centered\">",
"        191",
"       </td>",
"       <td class=\"centered\">",
"        239",
"       </td>",
"       <td class=\"centered\">",
"        287",
"       </td>",
"       <td class=\"centered\">",
"        335",
"       </td>",
"       <td class=\"centered\">",
"        382",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 2\"",
"       </td>",
"       <td class=\"centered\">",
"        62",
"       </td>",
"       <td class=\"centered\">",
"        157",
"       </td>",
"       <td class=\"centered\">",
"        50.1",
"       </td>",
"       <td class=\"centered\">",
"        200",
"       </td>",
"       <td class=\"centered\">",
"        251",
"       </td>",
"       <td class=\"centered\">",
"        301",
"       </td>",
"       <td class=\"centered\">",
"        351",
"       </td>",
"       <td class=\"centered\">",
"        401",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 3\"",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        160",
"       </td>",
"       <td class=\"centered\">",
"        52.4",
"       </td>",
"       <td class=\"centered\">",
"        210",
"       </td>",
"       <td class=\"centered\">",
"        262",
"       </td>",
"       <td class=\"centered\">",
"        314",
"       </td>",
"       <td class=\"centered\">",
"        367",
"       </td>",
"       <td class=\"centered\">",
"        419",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 4\"",
"       </td>",
"       <td class=\"centered\">",
"        64",
"       </td>",
"       <td class=\"centered\">",
"        163",
"       </td>",
"       <td class=\"centered\">",
"        54.7",
"       </td>",
"       <td class=\"centered\">",
"        219",
"       </td>",
"       <td class=\"centered\">",
"        274",
"       </td>",
"       <td class=\"centered\">",
"        328",
"       </td>",
"       <td class=\"centered\">",
"        383",
"       </td>",
"       <td class=\"centered\">",
"        438",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 5\"",
"       </td>",
"       <td class=\"centered\">",
"        65",
"       </td>",
"       <td class=\"centered\">",
"        165",
"       </td>",
"       <td class=\"centered\">",
"        57",
"       </td>",
"       <td class=\"centered\">",
"        228",
"       </td>",
"       <td class=\"centered\">",
"        285",
"       </td>",
"       <td class=\"centered\">",
"        342",
"       </td>",
"       <td class=\"centered\">",
"        399",
"       </td>",
"       <td class=\"centered\">",
"        456",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 6\"",
"       </td>",
"       <td class=\"centered\">",
"        66",
"       </td>",
"       <td class=\"centered\">",
"        168",
"       </td>",
"       <td class=\"centered\">",
"        59.3",
"       </td>",
"       <td class=\"centered\">",
"        237",
"       </td>",
"       <td class=\"centered\">",
"        297",
"       </td>",
"       <td class=\"centered\">",
"        356",
"       </td>",
"       <td class=\"centered\">",
"        415",
"       </td>",
"       <td class=\"centered\">",
"        474",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 7\"",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        170",
"       </td>",
"       <td class=\"centered\">",
"        61.6",
"       </td>",
"       <td class=\"centered\">",
"        246",
"       </td>",
"       <td class=\"centered\">",
"        308",
"       </td>",
"       <td class=\"centered\">",
"        370",
"       </td>",
"       <td class=\"centered\">",
"        431",
"       </td>",
"       <td class=\"centered\">",
"        493",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 8\"",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"       <td class=\"centered\">",
"        173",
"       </td>",
"       <td class=\"centered\">",
"        63.9",
"       </td>",
"       <td class=\"centered\">",
"        256",
"       </td>",
"       <td class=\"centered\">",
"        320",
"       </td>",
"       <td class=\"centered\">",
"        383",
"       </td>",
"       <td class=\"centered\">",
"        447",
"       </td>",
"       <td class=\"centered\">",
"        511",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 9\"",
"       </td>",
"       <td class=\"centered\">",
"        69",
"       </td>",
"       <td class=\"centered\">",
"        175",
"       </td>",
"       <td class=\"centered\">",
"        66.2",
"       </td>",
"       <td class=\"centered\">",
"        265",
"       </td>",
"       <td class=\"centered\">",
"        331",
"       </td>",
"       <td class=\"centered\">",
"        397",
"       </td>",
"       <td class=\"centered\">",
"        463",
"       </td>",
"       <td class=\"centered\">",
"        530",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 10\"",
"       </td>",
"       <td class=\"centered\">",
"        70",
"       </td>",
"       <td class=\"centered\">",
"        178",
"       </td>",
"       <td class=\"centered\">",
"        68.5",
"       </td>",
"       <td class=\"centered\">",
"        274",
"       </td>",
"       <td class=\"centered\">",
"        343",
"       </td>",
"       <td class=\"centered\">",
"        411",
"       </td>",
"       <td class=\"centered\">",
"        480",
"       </td>",
"       <td class=\"centered\">",
"        548",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5' 11\"",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"       <td class=\"centered\">",
"        180",
"       </td>",
"       <td class=\"centered\">",
"        70.8",
"       </td>",
"       <td class=\"centered\">",
"        283",
"       </td>",
"       <td class=\"centered\">",
"        354",
"       </td>",
"       <td class=\"centered\">",
"        425",
"       </td>",
"       <td class=\"centered\">",
"        496",
"       </td>",
"       <td class=\"centered\">",
"        566",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 0\"",
"       </td>",
"       <td class=\"centered\">",
"        72",
"       </td>",
"       <td class=\"centered\">",
"        183",
"       </td>",
"       <td class=\"centered\">",
"        73.1",
"       </td>",
"       <td class=\"centered\">",
"        292",
"       </td>",
"       <td class=\"centered\">",
"        366",
"       </td>",
"       <td class=\"centered\">",
"        439",
"       </td>",
"       <td class=\"centered\">",
"        512",
"       </td>",
"       <td class=\"centered\">",
"        585",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 1\"",
"       </td>",
"       <td class=\"centered\">",
"        73",
"       </td>",
"       <td class=\"centered\">",
"        185",
"       </td>",
"       <td class=\"centered\">",
"        75.4",
"       </td>",
"       <td class=\"centered\">",
"        302",
"       </td>",
"       <td class=\"centered\">",
"        377",
"       </td>",
"       <td class=\"centered\">",
"        452",
"       </td>",
"       <td class=\"centered\">",
"        528",
"       </td>",
"       <td class=\"centered\">",
"        603",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 2\"",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        188",
"       </td>",
"       <td class=\"centered\">",
"        77.7",
"       </td>",
"       <td class=\"centered\">",
"        311",
"       </td>",
"       <td class=\"centered\">",
"        389",
"       </td>",
"       <td class=\"centered\">",
"        466",
"       </td>",
"       <td class=\"centered\">",
"        544",
"       </td>",
"       <td class=\"centered\">",
"        622",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 3\"",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        190",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        320",
"       </td>",
"       <td class=\"centered\">",
"        400",
"       </td>",
"       <td class=\"centered\">",
"        480",
"       </td>",
"       <td class=\"centered\">",
"        560",
"       </td>",
"       <td class=\"centered\">",
"        640",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 4\"",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        193",
"       </td>",
"       <td class=\"centered\">",
"        82.3",
"       </td>",
"       <td class=\"centered\">",
"        329",
"       </td>",
"       <td class=\"centered\">",
"        412",
"       </td>",
"       <td class=\"centered\">",
"        494",
"       </td>",
"       <td class=\"centered\">",
"        576",
"       </td>",
"       <td class=\"centered\">",
"        658",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 5\"",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        196",
"       </td>",
"       <td class=\"centered\">",
"        84.6",
"       </td>",
"       <td class=\"centered\">",
"        338",
"       </td>",
"       <td class=\"centered\">",
"        423",
"       </td>",
"       <td class=\"centered\">",
"        508",
"       </td>",
"       <td class=\"centered\">",
"        592",
"       </td>",
"       <td class=\"centered\">",
"        677",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 6\"",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        198",
"       </td>",
"       <td class=\"centered\">",
"        86.9",
"       </td>",
"       <td class=\"centered\">",
"        348",
"       </td>",
"       <td class=\"centered\">",
"        435",
"       </td>",
"       <td class=\"centered\">",
"        521",
"       </td>",
"       <td class=\"centered\">",
"        608",
"       </td>",
"       <td class=\"centered\">",
"        695",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 7\"",
"       </td>",
"       <td class=\"centered\">",
"        79",
"       </td>",
"       <td class=\"centered\">",
"        201",
"       </td>",
"       <td class=\"centered\">",
"        89.2",
"       </td>",
"       <td class=\"centered\">",
"        357",
"       </td>",
"       <td class=\"centered\">",
"        446",
"       </td>",
"       <td class=\"centered\">",
"        535",
"       </td>",
"       <td class=\"centered\">",
"        624",
"       </td>",
"       <td class=\"centered\">",
"        714",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 8\"",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        203",
"       </td>",
"       <td class=\"centered\">",
"        91.5",
"       </td>",
"       <td class=\"centered\">",
"        366",
"       </td>",
"       <td class=\"centered\">",
"        458",
"       </td>",
"       <td class=\"centered\">",
"        549",
"       </td>",
"       <td class=\"centered\">",
"        641",
"       </td>",
"       <td class=\"centered\">",
"        732",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 9\"",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        206",
"       </td>",
"       <td class=\"centered\">",
"        93.8",
"       </td>",
"       <td class=\"centered\">",
"        375",
"       </td>",
"       <td class=\"centered\">",
"        469",
"       </td>",
"       <td class=\"centered\">",
"        563",
"       </td>",
"       <td class=\"centered\">",
"        657",
"       </td>",
"       <td class=\"centered\">",
"        750",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 10\"",
"       </td>",
"       <td class=\"centered\">",
"        82",
"       </td>",
"       <td class=\"centered\">",
"        208",
"       </td>",
"       <td class=\"centered\">",
"        96.1",
"       </td>",
"       <td class=\"centered\">",
"        384",
"       </td>",
"       <td class=\"centered\">",
"        481",
"       </td>",
"       <td class=\"centered\">",
"        577",
"       </td>",
"       <td class=\"centered\">",
"        673",
"       </td>",
"       <td class=\"centered\">",
"        769",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6' 11\"",
"       </td>",
"       <td class=\"centered\">",
"        83",
"       </td>",
"       <td class=\"centered\">",
"        211",
"       </td>",
"       <td class=\"centered\">",
"        98.4",
"       </td>",
"       <td class=\"centered\">",
"        394",
"       </td>",
"       <td class=\"centered\">",
"        492",
"       </td>",
"       <td class=\"centered\">",
"        590",
"       </td>",
"       <td class=\"centered\">",
"        689",
"       </td>",
"       <td class=\"centered\">",
"        787",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7' 0\"",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        213",
"       </td>",
"       <td class=\"centered\">",
"        100.7",
"       </td>",
"       <td class=\"centered\">",
"        403",
"       </td>",
"       <td class=\"centered\">",
"        504",
"       </td>",
"       <td class=\"centered\">",
"        604",
"       </td>",
"       <td class=\"centered\">",
"        705",
"       </td>",
"       <td class=\"centered\">",
"        806",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PBW: predicted body weight.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the NHLBI ARDS Network.",
"     <a href=\"file://www.ardsnet.org/node/77460\" target=\"_blank\">",
"      file://www.ardsnet.org/node/77460",
"     </a>",
"     (Accessed on November 20, 2012). Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8576=[""].join("\n");
var outline_f8_24_8576=null;
var title_f8_24_8577="Laparoscopic mobilization of the intra-abdominal esophagus";
var content_f8_24_8577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic mobilization of the intra-abdominal esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intraoperative photograph shows the mobilized intra-abdominal esophagus (large arrow) and the crura of the diaphragm (smaller arrows). The esophagus is mobilized without tension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Rosen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8577=[""].join("\n");
var outline_f8_24_8577=null;
var title_f8_24_8578="Dilation and curettage (D and C)";
var content_f8_24_8578=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/24/8578/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8578/contributors\" id=\"au6081\">",
"       Dale W Stovall, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/24/8578/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8578/contributors\" id=\"se5145\">",
"       William J Mann, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?8/24/8578/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8578/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?8/24/8578?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DILATION AND CURETTAGE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Dilation and curettage (D and C) is a procedure in which material from the inside of the uterus is removed. The \"dilation\" refers to dilation of the cervix, the lower part of the uterus that opens into the vagina (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). \"Curettage\" refers to the scraping or removal of tissue lining the uterine cavity (endometrium) with a surgical instrument called a curette.",
"    </p>",
"    <p>",
"     D and C may be done to diagnose a problem, such as abnormal uterine bleeding, or as a treatment for miscarriage or excessive bleeding. This topic discusses the reasons for D and C, how to prepare for the procedure, and what to expect afterwards.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR D AND C",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of reasons a D and C might be performed. In some cases, the procedure is used to gain information about the uterus to diagnose a medical condition (called diagnostic D and C). In other cases, the procedure is used to treat a medical problem or condition (called therapeutic D and C).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Diagnostic D and C",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary reason for a diagnostic D and C is to obtain samples of the endometrium to evaluate abnormal uterine bleeding or abnormal cells that may be from the uterus that were found during routine screening for cervical cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In most cases, a healthcare provider will try to obtain a tissue sample with an office procedure called endometrial biopsy. In some cases, endometrial biopsy is not possible or insufficient tissue is obtained. When this occurs, D and C must be done to obtain an adequate tissue sample.",
"    </p>",
"    <p>",
"     Diagnostic D and C is sometimes done with hysteroscopy; this involves dilating the cervix and inserting a small instrument to examine and photograph the inside of the uterus. The images are displayed on a monitor, allowing the physician to visualize the endometrium. This helps the physician to avoid missing small polyps and ensures that the most visibly abnormal areas are sampled. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"      \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A pathologist then examines the tissue with a microscope to establish certain diagnoses, including endometrial (uterine) cancer, endometrial polyps, or precancerous conditions of the lining of the uterus (endometrial hyperplasia). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"      \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Therapeutic D and C",
"     </span>",
"     &nbsp;&mdash;&nbsp;Therapeutic D and C is done to remove the contents of the uterus in the following circumstances:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Miscarriage",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some miscarriages, the tissues from a pregnancy are passed completely. In other cases, a D and C is needed to remove this tissue or to ensure that all of it has been passed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"      \"Patient information: Miscarriage (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Abortion",
"     </span>",
"     &nbsp;&mdash;&nbsp;A D and C can be done to remove the contents of the uterus when a woman chooses to end a pregnancy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"      \"Overview of pregnancy termination\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Treatment of molar pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A molar pregnancy occurs when a tumor forms in place of normal pregnancy placenta. It is often treated with a D and C. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link\">",
"      \"Gestational trophoblastic disease: Management of hydatidiform mole\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Prolonged or excessive vaginal bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;D and C may be done as a treatment in some cases of prolonged or excessive bleeding that do not respond to medical treatment. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"      \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Postpartum hemorrhage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Curettage may be done to manage excessive bleeding after delivery of an infant (postpartum hemorrhage). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"      \"Overview of postpartum hemorrhage\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      PREPARING FOR D AND C",
"     </span>",
"    </p>",
"    <p>",
"     Some patients will need to have blood testing before D and C (such as a blood count or tests of clotting factors), although this is not always necessary. You should not eat or drink anything starting the night before the procedure. You will need someone to accompany you home because it will not be safe to drive after receiving anesthesia, which causes sedation.",
"    </p>",
"    <p>",
"     You may need to have a device or medication placed in or near the cervix the day before your procedure. The purpose is to safely and gradually enlarge the cervical opening, reducing the risk of cervical injury. Devices are used when the cervix must be dilated to a larger size than is typically needed for D and C, such as with pregnancy terminations and some types of hysteroscopy. You may be instructed to insert a medicine in your vagina to soften your cervix prior to the procedure.",
"    </p>",
"    <p>",
"     After arriving for the procedure, a nurse may place an intravenous line, which can be used to give fluids and medicine before, during, and after the procedure. The nurse or doctor will review your medical history, list of medications used, and any drug allergies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      D AND C PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     D and C can be performed in an operating room in a hospital or clinic. Your blood pressure, pulse, and blood oxygen levels are monitored during the procedure. The procedure takes 15 to 30 minutes to complete.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Anesthesia",
"     </span>",
"     &nbsp;&mdash;&nbsp;The procedure can be done using general, regional, or local block anesthesia. The type of anesthesia chosen depends upon the reason for the procedure as well as your medical history.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CARE AFTER D AND C",
"     </span>",
"    </p>",
"    <p>",
"     After the procedure, you will rest in a recovery or post-anesthesia care unit for a few hours. This is necessary to monitor for excessive vaginal bleeding or other complications, and allows time for you to recover from the anesthesia. If you were given general anesthesia, you may have nausea and vomiting, which can be treated with medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Recovery at home",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should be able to resume your regular activities within a day or two. Mild cramping and spotting may occur for a few hours or days; cramping can be treated with nonsteroidal antiinflammatory medications such as ibuprofen (Advil&reg;, Motrin&reg;). You should not put anything into the vagina (tampons, douches) during this time and should ask when you can safely have sexual intercourse. Your next menstrual period usually occurs within four to six weeks of the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      When to call for help",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should call your physician if you develop fever (temperature greater than 101&ordm; F), cramps lasting longer than 48 hours, increasing rather than decreasing pain, prolonged or heavy bleeding, or foul-smelling vaginal discharge.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      D AND C COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     D and C is a commonly performed procedure that is usually very safe. Yet as with any operation, complications occur. Complications of D and C can include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Uterine perforation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Uterine perforation occurs when one of the surgical instruments makes a hole in the uterus. It is more common when the procedure is done during pregnancy due to softening of the uterine wall.",
"    </p>",
"    <p>",
"     Fortunately, most uterine perforations heal on their own and do not require any treatment. Two potential problems caused by perforation are bleeding from injury to a blood vessel and injury to other internal organs. A second procedure may be needed to repair these types of injury.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Cervical injury",
"     </span>",
"     &nbsp;&mdash;&nbsp;Injuries to the cervix can occur during dilation or from trauma related to the curettage. Lacerations (cuts) to the cervix are managed with pressure to the area, application of medications that help stop bleeding, or in some cases, stitches in the cervix.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Infection from D and C is rare.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Intrauterine adhesions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adhesions (areas of scar tissue) can sometimes form in the uterus following D and C. Adhesion is most common when D and C is performed during or after pregnancy. In some cases, this can lead to abnormalities in the menstrual cycle, painful menstrual cycles, infertility, or miscarriage. If adhesions are extensive, you can be treated with hormones to encourage growth of healthy uterine tissue and the scar tissue can be removed with a surgical procedure. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"      \"Intrauterine adhesions\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287440626\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263300643\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/33/29202?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23747?source=see_link\">",
"      Patient information: Uterine cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263300635\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=see_link\">",
"      Dilation and curettage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=see_link\">",
"      Endometrial sampling procedures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"      Overview of pregnancy termination",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4453?source=see_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28409?source=see_link\">",
"      Termination of pregnancy: Second trimester",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23015?source=see_link\">",
"      Gestational trophoblastic disease: Management of hydatidiform mole",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"      Intrauterine adhesions",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"      www.mayoclinic.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?8/24/8578/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?8/24/8578?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8578/abstract/2\">",
"      Chen SS, Lee L. Reappraisal of endocervical curettage in predicting cervical involvement by endometrial carcinoma. J Reprod Med 1986; 31:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8578/abstract/3\">",
"      Gebauer G, Hafner A, Siebzehnr&uuml;bl E, Lang N. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol 2001; 184:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f8_24_8578=[""].join("\n");
var outline_f8_24_8578=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DILATION AND CURETTAGE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR D AND C",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           PREPARING FOR D AND C",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           D AND C PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CARE AFTER D AND C",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           D AND C COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f8_24_8579="Melasma lip";
var content_f8_24_8579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented patch is present on the upper lip in this patient with melasma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8579=[""].join("\n");
var outline_f8_24_8579=null;
var title_f8_24_8580="Throat PI";
var content_f8_24_8580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Throat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 720px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a cross-section of the head and neck. The throat includes the area from the back of the nose and mouth to the windpipe and esophagus (the tube that carries food from the mouth to the stomach).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8580=[""].join("\n");
var outline_f8_24_8580=null;
var title_f8_24_8581="Rizatriptan: Pediatric drug information";
var content_f8_24_8581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rizatriptan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"    see \"Rizatriptan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/47/37621?source=see_link\">",
"    see \"Rizatriptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Maxalt-MLT&reg;;",
"     </li>",
"     <li>",
"      Maxalt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Rizatriptan&reg;;",
"     </li>",
"     <li>",
"      CO Rizatriptan;",
"     </li>",
"     <li>",
"      CO Rizatriptan ODT;",
"     </li>",
"     <li>",
"      JAMP-Rizatriptan;",
"     </li>",
"     <li>",
"      Mar-Rizatriptan;",
"     </li>",
"     <li>",
"      Maxalt RPD&trade;;",
"     </li>",
"     <li>",
"      Maxalt&trade;;",
"     </li>",
"     <li>",
"      Mylan-Rizatriptan ODT;",
"     </li>",
"     <li>",
"      Sandoz-Rizatriptan ODT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1035154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Serotonin 5-HT",
"       <sub>",
"        1D",
"       </sub>",
"       Receptor Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1035184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=see_link\">",
"      see \"Rizatriptan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Migraine, acute treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents &ge;6 years:",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of multiple rizatriptan doses in a 24-hour period has not been established for pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;40 kg: 5 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;40 kg: 10 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 5-10 mg, repeat after 2 hours if significant relief is not attained; maximum: 30 mg in a 24-hour period;",
"     <b>",
"      Note:",
"     </b>",
"     In patients with risk factors for coronary artery disease, following adequate evaluation to establish the absence of coronary artery disease, the initial dose should be administered in a setting where response may be evaluated (physician's office or similarly staffed setting). ECG monitoring may be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment with concomitant propranolol:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents 6-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;40 kg: Do not use rizatriptan",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;40 kg: 5 mg as a single dose; maximum: 5 mg in a 24-hour period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 5 mg; may repeat after 2 hours; maximum daily dose: 15 mg in a 24-hour period",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxalt&reg;: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxalt-MLT&reg;: 5 mg [contains phenylalanine 1.05 mg/tablet; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxalt-MLT&reg;: 10 mg [contains phenylalanine 2.1 mg/tablet; peppermint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13652357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Orally disintegrating tablets (Maxalt-MLT&reg;): Do not remove the blister from the pouch until ready to use; blister pouch should be opened by peeling back (not pushing through foil) and with dry hands; place tablet on the tongue to dissolve; do not crush, break, or chew; additional liquids are not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1035171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).  MLT tablets should remain in blister pack until administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1035155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of migraine with or without aura (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F219032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, flushing, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, euphoria, fatigue (dose related; more common in adults), headache, hypoesthesia, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck, throat, and jaw pain/tightness/pressure; paresthesia; tremor; weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Feeling of heaviness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis/anaphylactoid reactions, angina, angioedema, blurred vision, bradycardia, confusion, edema, hallucination (children), hearing impairment, hypertensive crisis, memory impairment, MI, myocardial ischemia, pruritus, seizure, syncope, tachycardia, tinnitus, tongue edema, toxic epidermal necrolysis, vasospasm, vertigo, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1035159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rizatriptan or any component; known or suspected ischemic heart disease (eg, angina pectoris,  MI, silent MI); other significant underlying cardiovascular diseases; coronary artery vasospasm, including Prinzmetal's angina; uncontrolled hypertension; history of stroke or transient ischemic attack; peripheral vascular disease; ischemic bowel disease; management of hemiplegic or basilar migraine; concomitant use (within last 24 hours) of ergotamine derivatives and/or ergotamine-containing medications (eg, methysergide, dihydroergotamine) or other 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist (eg, triptans); concomitant use (within 2 weeks) of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13652335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with controlled hypertension; temporary increases in peripheral vascular resistance and blood pressure may occur; significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension. Use with caution in patients with impaired hepatic function or receiving dialysis. Other potentially serious neurological conditions should be ruled out prior to acute migraine therapy; if a patient does not respond to the first dose of rizatriptan, the diagnosis of migraine should be reconsidered. Rizatriptan could potentially bind to melanin-containing tissues (eg, eye) due to chemical properties leading to toxicity with extended use; animal data did not show ophthalmologic toxicities. Some adverse effects may be dose-related including: Fatigue, somnolence, chest pain, and weakness; fatigue more common in adults than pediatric patients (&le;30% vs ~1%).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1035160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious coronary events, including coronary artery vasospasm, transient ischemia, acute MI, life-threatening arrhythmias (eg, ventricular tachycardia/fibrillation), and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration; avoid use in patients with risk factors for coronary artery disease, unless cardiovascular disease can be ruled out; consider administering first dose under close supervision to patients at high risk for coronary disease. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal&rsquo;s angina before receiving additional doses. If dosing resumed and symptoms recur, ECG monitoring is recommended. Periodically evaluate cardiovascular system in patients with risk factors for coronary artery disease. Cerebrovascular events (eg, cerebral hemorrhage, subarachnoid hemorrhage, stroke) have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist (triptan) administration. Vasospasm-related events (eg, peripheral vascular ischemia, Raynaud&rsquo;s syndrome, and colonic ischemia with abdominal pain and bloody diarrhea) have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonists; transient and permanent blindness and significant partial vision loss have been very rarely reported; further evaluation is recommended in patients with signs and symptoms suggestive of reduced peripheral arterial blood flow following 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist (eg, triptan) use. Medication overuse headache may occur with overuse of acute migraine medications; a significant increase in frequency of migraine attacks or migraine-like daily headaches may occur; withdrawal of overused medication and treatment of withdrawal symptoms may be required. Potentially fatal serotonin syndrome may occur when triptans are used in combination with SSRIs (eg, fluoxetine, sertraline) or SNRIs (eg, venlafaxine); monitor carefully if the two drugs are used concomitantly. Maxalt-MLT&reg; tablets contain phenylalanine which should be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: May increase the serum concentration of Rizatriptan. Management: Rizatriptan adult dose should be reduced to 5 mg in patients who are also being treated with propranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1035170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Time to reach peak serum concentration is delayed by 1 hour in presence of food; AUC not significantly affected",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pregnancy registry has been established to monitor outcomes of women exposed to rizatriptan during pregnancy (800-986-8999). Preliminary data from the pregnancy registry does not show an increased risk of congenital malformations (Fiore, 2005). In some animal studies, administration was associated with decreased weight gain, developmental toxicity and increased mortality in the offspring. Teratogenic effects were not observed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1035188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Headache severity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1035173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1035175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 110-140 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via monoamine oxidase-A to a major inactive and a minor (14%) active metabolite; first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~45%; AUC in females reported to be 30% higher than males",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Maxalt&reg;: 1-1.5 hours; Maxalt-MLT&reg;: 1.6-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (82%, ~14%  as unchanged drug); feces (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Reported AUC 44% higher in dialysis patients compared to normal renal function; effects of hemodialysis or peritoneal dialysis are unknown",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1035192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/47/37621?source=see_link\">",
"      see \"Rizatriptan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For orally disintegrating tablets (Maxalt-MLT&reg;), do not open blister pack before using. Open with dry hands, place on tongue, and allow to dissolve (dissolved tablet will be swallowed with saliva). After initial dose and relief, a second dose may be taken after 2 hours if migraine returns; no more than 2 doses should be used without consulting prescriber. May cause dizziness, drowsiness, dry mouth, skin flushing or hot flashes, mild abdominal discomfort, nausea, or vomiting. Report immediately any chest pain, palpitations, or irregular heartbeat; severe dizziness, acute headache, stiff or painful neck, or facial swelling; muscle weakness or pain; changes in mental acuity; blurred vision or eye pain; or excessive perspiration or urination.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13652358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety of treating &gt;4 migraines per month is not established; rizatriptan is not indicated for migraine prophylaxis; safety and efficacy for cluster headaches has not been established.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahonen K, H&auml;m&auml;l&auml;inen ML, Eerola M. et al, \"A Randomized Trial of Rizatriptan in Migraine Attacks in Children,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2006, 67(7):1135-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8581/abstract-text/16943370/pubmed\" id=\"16943370\" target=\"_blank\">",
"        16943370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis D, Ashwal S, Hershey A, et al, \"Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 63(12):2215-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8581/abstract-text/15623677/pubmed\" id=\"15623677\" target=\"_blank\">",
"        15623677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Visser WH, Winner P, Strohmaier K, et al, \"Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: Results From a Double-Blind, Single-Attack Study and Two Open-Label, Multiple-Attack Studies,\"",
"      <i>",
"       Headache",
"      </i>",
"      , 2004, 44(9):891-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8581/abstract-text/15447698/pubmed\" id=\"15447698\" target=\"_blank\">",
"        15447698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winner P, Lewis D, Visser WH, et al, \"Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Study,\"",
"      <i>",
"       Headache",
"      </i>",
"      , 2002, 42(1):49-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8581/abstract-text/12005275/pubmed\" id=\"12005275\" target=\"_blank\">",
"        12005275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17059 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.13-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8581=[""].join("\n");
var outline_f8_24_8581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035154\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035184\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218975\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218961\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13652357\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035171\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035155\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219032\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035159\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13652335\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035160\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300011\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218969\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035170\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218971\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218982\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035188\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035173\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035175\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1035192\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13652358\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/14/29925?source=related_link\">",
"      Rizatriptan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/47/37621?source=related_link\">",
"      Rizatriptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_24_8582="Diphenhydramine and phenylephrine: Drug information";
var content_f8_24_8582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/25/23957?source=see_link\">",
"    see \"Diphenhydramine and phenylephrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6803585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aldex&reg; CT;",
"     </li>",
"     <li>",
"      Benadryl-D&reg; Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Benadryl-D&reg; Children's Allergy &amp; Sinus [OTC];",
"     </li>",
"     <li>",
"      Dimetapp&reg; Children&rsquo;s Nighttime Cold &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Night Time Cold &amp; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6803589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Ethanolamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6806304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic symptoms, nasal congestion:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldex&reg; CT: 1-2 tablets every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OTC labeling:",
"     <b>",
"      Note:",
"     </b>",
"     General dosing guidelines; refer to specific product labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10-20 mL every 4 hours as needed (maximum: 6 doses/24 hours)",
"     <b>",
"      or",
"     </b>",
"     1 tablet every 4 hours as needed (maximum: 6 doses/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6806303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Allergic symptoms, nasal congestion:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldex&reg; CT:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years: One-half to 1 tablet every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OTC labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;6 years: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Benadryl-D&reg; Children's Allergy &amp; Sinus: 5 mL every 4 hours as needed (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dimetapp&reg; Children's Nighttime Cold and Congestion, Triaminic&reg; Children's Night Time Cold &amp; Cough: 10 mL every 4 hours as needed (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6806305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6806306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Benadryl-D&reg; Children's Allergy &amp; Sinus: Diphenhydramine hydrochloride 12.5 mg and phenylephrine hydrochloride 5 mg per 5 mL (118 mL) [ethanol free, sugar free; contains sodium 10 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dimetapp&reg; Children's Nighttime Cold and Congestion: Diphenhydramine hydrochloride 6.25 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (120 mL) [ethanol free, sugar free; contains propylene glycol, sodium 4 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Triaminic&reg; Children's Night Time Cold &amp; Cough: Diphenhydramine hydrochloride 6.25 mg and phenylephrine hydrochloride 2.5 mg per 5 mL (118 mL) [contains ethanol, propylene glycol, sodium 6 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Benadryl-D&reg; Allergy &amp; Sinus: Diphenhydramine hydrochloride 25 mg and phenylephrine hydrochloride 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aldex&reg; CT: Diphenhydramine hydrochloride 12.5 mg and phenylephrine hydrochloride 5 mg [contains phenylalanine; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6803587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6803592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of symptoms of allergic rhinitis, sinusitis, and other upper respiratory conditions, including sinus/nasal congestion, sneezing, stuffy/runny nose, itchy/watery eyes, and cough",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6806263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Chest tightness, extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Chills, confusion, coordination impaired, dizziness, drowsiness, euphoria, excitation, fatigue, headache, insomnia, irritability, nervousness, neuritis, restlessness, sedation, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Early menses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes, epigastric distress, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchial secretions (thickening), nasal congestion, throat tightness, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6803598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenhydramine, phenylephrine, or any component of the formulation; concurrent use with other products containing diphenhydramine (including topical); use with or within 14 days of MAO inhibitors; newborns; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6803599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; may cause excitability. Do not exceed pediatric dosing recommendations. If no recommendations exist on OTC labeling for patient&rsquo;s age, the product should",
"     <b>",
"      not",
"     </b>",
"     be administered without the guidance of a physician. Not for OTC use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Patients with hypertension, thyroid disease, diabetes mellitus, glaucoma, cardiovascular disease, or prostatic hyperplasia should consult healthcare provider prior to use. Patients with chronic cough (associated with COPD or smoking) and/or productive cough (eg, copious amounts of phlegm) should be evaluated by a healthcare provider prior to use. Ask healthcare provider prior to using with sedatives. If symptoms or cough do not improve, are accompanied by fever, or persist &gt;7 days during use, consult a physician. Do not exceed recommended dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6833766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6806266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6806273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Aldex-CT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-5 mg (100): $294.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Delsym Nght Time Cgh/Cld Child Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-5 mg/5 mL (120 mL): $8.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Delsym Night Cgh/Cold Children Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-2.5 mg/5 mL (118 mL): $8.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Delsym Night Time Cough/Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-2.5 mg/5 mL (120 mL): $8.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Dimetapp Night Cold/Congestion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-2.5 mg/5 mL (118 mL): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Night Time Cgh/Cold Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-2.5 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Triaminic Cold/Cough NightTime Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-2.5 mg/5 mL (118 mL): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Benadryl-D Allergy/Sinus Child Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-5 mg/5 mL (118 mL): $5.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (PediaCare Childrens Nightrest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5-5 mg/5 mL (118 mL): $5.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Triaminic Night Time Cold/Cgh Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-2.5 mg/5 mL (118 mL): $5.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benadryl-D Allergy/Sinus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-10 mg (24): $4.46",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6806269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diphenhydramine is an H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenylephrine is a potent, direct-acting alpha-adrenergic stimulator.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6806271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9019 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8582=[""].join("\n");
var outline_f8_24_8582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803585\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803589\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806304\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806303\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806305\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806306\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803587\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803592\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806263\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803598\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803599\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299211\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833766\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806266\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806273\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321872\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806269\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6806271\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9019\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9019|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/25/23957?source=related_link\">",
"      Diphenhydramine and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_24_8583="Olmesartan: Drug information";
var content_f8_24_8583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olmesartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10677?source=see_link\">",
"    see \"Olmesartan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/17/2326?source=see_link\">",
"    see \"Olmesartan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benicar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Olmetec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: Usual starting dose is 20 mg once daily; if initial response is inadequate, may be increased to 40 mg once daily after 2 weeks. May administer with other antihypertensive agents if blood pressure inadequately controlled with olmesartan. Consider lower starting dose in patients with possible depletion of intravascular volume (eg, patients receiving diuretics).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9944092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/17/2326?source=see_link\">",
"      see \"Olmesartan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Children 6-16 years: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     20 kg to &lt;35 kg: Initial: 10 mg once daily; if initial response inadequate after 2 weeks, dose may be increased (maximum: 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;35 kg: Initial: 20 mg once daily; if initial response inadequate after 2 weeks, dose may be increased (maximum: 40 mg/day)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary per labeling; however, may consider starting at 5-10 mg/day (due to concomitant disease or age changes).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F203493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific guidelines for dosage adjustment; patients undergoing hemodialysis have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F203494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No initial dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as medoxomil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benicar&reg;: 5 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension with or without concurrent use of other antihypertensive agents",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benicar&reg; may be confused with Mevacor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3%), headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypertriglyceridemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, CPK increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, alopecia, anaphylaxis, angioedema, arthritis, gastroenteritis, hypercholesterolemia, hyperkalemia, hyperlipidemia, hyperuricemia, liver enzymes increased, peripheral edema, rhabdomyolysis, serum creatinine increased, sprue-like symptoms, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with olmesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use olmesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Olmesartan. Management: Administer olmesartan at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F203484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Does not affect olmesartan bioavailability. Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of olmesartan (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F203474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F203471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benicar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $97.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $359.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $501.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F203462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, serum potassium",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Almetec (MX);",
"     </li>",
"     <li>",
"      Alteis (FR);",
"     </li>",
"     <li>",
"      Alzor (PH);",
"     </li>",
"     <li>",
"      Benetor (IE);",
"     </li>",
"     <li>",
"      Benicar (BR);",
"     </li>",
"     <li>",
"      Cardioplus (CN);",
"     </li>",
"     <li>",
"      Iltux (EC);",
"     </li>",
"     <li>",
"      Olmec (AR);",
"     </li>",
"     <li>",
"      Olmesta (BG);",
"     </li>",
"     <li>",
"      Olmetec (AT, AU, BE, CH, CL, CO, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IL, IT, KP, MY, NI, NL, NO, PE, PH, PT, SG, SV, TH, TW, UY, VE);",
"     </li>",
"     <li>",
"      Olmezar (PH);",
"     </li>",
"     <li>",
"      Omesar (IE);",
"     </li>",
"     <li>",
"      Votum (CH, DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a selective and competitive, nonpeptide angiotensin II receptor antagonist, olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; olmesartan interacts reversibly at the AT1 and AT2 receptors of many tissues and has slow dissociation kinetics; its affinity for the AT1 receptor is 12,500 times greater than the AT2 receptor. Angiotensin II receptor antagonists may induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, they do not affect the response to bradykinin, and are less likely to be associated with nonrenin-angiotensin effects (eg, cough and angioedema). Olmesartan increases urinary flow rate and, in addition to being natriuretic and kaliuretic, increases excretion of chloride, magnesium, uric acid, calcium, and phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 17 L; does not cross the blood-brain barrier (animal studies)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Olmesartan medoxomil is hydrolyzed in the GI tract to active olmesartan. No further metabolism occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 26%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: All as unchanged drug: Feces (50% to 65%); urine (35% to 50%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K and Kjekshus J, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haller H, Ito S, Izzo JL Jr, et al, &ldquo;Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(10):907-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/21388309/pubmed\" id=\"21388309\" target=\"_blank\">",
"        21388309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Imai E, Chan JCN, Ito S, et al, &ldquo;Effects of Olmesartan on Renal and Cardiovascular Outcomes in Type 2 Diabetes With Overt Nephropathy: A Multicentre, Randomized, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Diabetologia",
"      </i>",
"      , 2011, 54(12):2978-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/21993710/pubmed\" id=\"21993710\" target=\"_blank\">",
"        21993710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubio-Tapia A, Herman ML, Ludvigsson JF, et al, \"Severe Spruelike Enteropathy Associated With Olmesartan,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/22728033/pubmed\" id=\"22728033\" target=\"_blank\">",
"        22728033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/24/8583/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10061 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-293D88DB16-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8583=[""].join("\n");
var outline_f8_24_8583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709179\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203488\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203507\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203491\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944092\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203492\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203493\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203494\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203464\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203451\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203466\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203465\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914230\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203505\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203469\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203454\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837691\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203458\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203484\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203460\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203472\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203497\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203474\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203471\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203462\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539905\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203453\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203468\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10677?source=related_link\">",
"      Olmesartan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/17/2326?source=related_link\">",
"      Olmesartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_24_8584="Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression";
var content_f8_24_8584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mindfulness based cognitive therapy as maintenance treatment for unipolar major depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/24/8584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8584/contributors\">",
"     Zindel Segal, PhD, C.Psych",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/24/8584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8584/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/24/8584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8584/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/24/8584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26977519\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is a group program that is generally used to delay or prevent recurrence of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/1\">",
"     1",
"    </a>",
"    ], but may also reduce depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/2\">",
"     2",
"    </a>",
"    ]. The treatment combines the clinical application of mindfulness meditation with elements of cognitive-behavioral therapy, and was first developed in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 23 controlled or case-controlled studies found that mindfulness meditation may enhance attention, memory, and some executive functions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/6\">",
"     6",
"    </a>",
"    ]. Neuroimaging studies have found that meditation may possibly be associated with functional [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and structural brain changes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], but the clinical significance of these preliminary findings are unknown. &nbsp;",
"   </p>",
"   <p>",
"    This topic reviews the use of mindfulness based cognitive therapy for the maintenance treatment of patients with recurrent unipolar depression. The initial treatment of depression and treatment of resistant depression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2239853\">",
"    <span class=\"h1\">",
"     INDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is indicated for maintenance treatment of euthymic patients who have suffered multiple episodes of unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. (The evidence suggests that the therapy is effective for patients with a history of at least three episodes.) The therapy can be used alone or in conjunction with pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/11,12,15,16\">",
"     11,12,15,16",
"    </a>",
"    ]. Treatment guidelines from both the United Kingdom National Institute for Health and Clinical Excellence and the Canadian Network for Mood and Anxiety Treatments recommend mindfulness-based cognitive therapy for maintenance treatment of major depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Practice guidelines from the American Psychiatric Association also suggest that mindfulness-based cognitive therapy can reduce recurrence of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, the therapy may reduce residual depressive symptoms, regardless of the number of prior episodes of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2240511\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is contraindicated for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired attention and concentration due to acute major depression or acute comorbid mental disorders that require treatment prior to maintenance therapy for major depression (eg, substance use disorders). Mindfulness meditation requires intact cognition.",
"     </li>",
"     <li>",
"      Active suicidal ideation and no other current maintenance treatment.",
"     </li>",
"     <li>",
"      Untreated trauma. Treating trauma requires patients to discuss the content of traumatic experiences. Mindfulness-based cognitive therapy places more emphasis upon observing thoughts and feelings and less upon responding to their content. &nbsp;",
"     </li>",
"     <li>",
"      An inability to tolerate the intense, difficult emotions that are elicited, including sadness, anxiety, and anger.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26977526\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is a skills-training group program that combines the clinical application of mindfulness meditation with elements of cognitive-behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Mindfulness is purposeful, nonjudgmental attention to the present moment, which is developed through meditation and other practices [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. CBT is based upon the theory that maladaptive thoughts and behaviors lead to psychopathology; the clinician addresses these dysfunctional cognitions and the patient tries to change the resulting problematic behaviors.",
"   </p>",
"   <p>",
"    There are similarities between mindfulness based cognitive therapy and CBT. Both treatments teach patients to identify triggers and symptoms of relapse, and to develop a behavior plan for avoiding relapse. Other similarities include directing patients to observe their thoughts and to rate activities for the pleasure and sense of mastery they provide.",
"   </p>",
"   <p>",
"    Both treatments also address dysfunctional, ruminative, and depressogenic thoughts (eg, &ldquo;I&rsquo;m so weak&rdquo; or &ldquo;I&rsquo;ve let others down&rdquo;) that are induced by distressing events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/17\">",
"     17",
"    </a>",
"    ]. During an acute episode of major depression, the patient experiences dysphoria and dysfunctional thoughts, along with other symptoms. Some studies suggest a connection develops between dysphoria and dysfunctional thoughts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. Following remission, something distressing may induce sadness, which may then reactivate self-criticism and other dysfunctional thoughts about inadequacy and failure, even if they are not relevant to the current situation. Patients may believe their remission is threatened and ask, &ldquo;What&rsquo;s wrong with me?&rdquo; This rumination may lead to a cascade of thoughts and emotions that results in relapse of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    What distinguishes mindfulness based cognitive therapy is its emphasis upon accepting dysfunctional thoughts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/24\">",
"     24",
"    </a>",
"    ]. By contrast, CBT emphasizes changing dysfunctional thoughts by gathering evidence to dispute their veracity.",
"   </p>",
"   <p>",
"    The hypothesized mechanism of action for mindfulness-based cognitive therapy is that it helps patients to [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5,24-29\">",
"     5,24-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Observe and accept dysfunctional thoughts rather than avoid or suppress them",
"     </li>",
"     <li>",
"      View their thoughts as ideas and momentary mental events rather than facts",
"     </li>",
"     <li>",
"      Cultivate self-compassion",
"     </li>",
"     <li>",
"      Increase their ability to tolerate dysphoria &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26977533\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician conducting mindfulness based cognitive therapy individually interviews prospective patients to assess their suitability and explain what occurs during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/30\">",
"     30",
"    </a>",
"    ]. Prior to this interview, the patient should read a handout (",
"    <a class=\"graphic graphic_table graphicRef61850 \" href=\"UTD.htm?35/19/36157\">",
"     table 1",
"    </a>",
"    ) that explains that the therapy is a maintenance treatment for depression, that homework is part of the treatment, and the difficulty of facing unpleasant emotions and thoughts.",
"   </p>",
"   <p>",
"    In determining whether the patient is appropriate for mindfulness based cognitive therapy, the clinician should confirm that the patient has suffered multiple episodes of unipolar major depression; the evidence suggests that the therapy is effective for patients with a history of at least three episodes. In addition, the patient should have recovered from the most recent episode [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. The Patient Health Questionnaire &ndash; Nine Item (PHQ-9) is a well-validated, widely used, self-report measure that can facilitate assessment of the patient&rsquo;s current depressive status (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with residual symptoms may be suitable, depending upon the specific nature of the symptoms. Suicidal patients without any other treatment are not appropriate for mindfulness-based cognitive therapy. In addition, it is critical to ascertain if attention and concentration are intact, with both the interview (eg, &ldquo;Is reading a problem? Can you concentrate for long periods of time? Can you follow the plot while watching a movie?&rdquo;) and mental status examination.",
"   </p>",
"   <p>",
"    In assessing the patient&rsquo;s commitment to attend the weekly sessions and complete the daily homework, the clinician should discuss the value of persisting with treatment if results are not immediately apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. An analogy can be offered that training one&rsquo;s cognition is like training a muscle; it takes practice. Similarly, depressed patients often have to take an antidepressant medication for several weeks before they notice any benefit. The intention is to enable patients to estimate their readiness for mindfulness-based cognitive therapy, rather than to persuade them to enroll.",
"   </p>",
"   <p>",
"    Logistical and practical aspects of treatment are also discussed during the individual interview, including the policy for tardiness, missed appointments, and payment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26977540\">",
"    <span class=\"h1\">",
"     DELIVERING MINDFULNESS BASED COGNITIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is a group program that combines training in mindfulness meditation with cognitive-behavioral therapy (CBT) techniques. The therapy is based upon a treatment manual (book) that describes how the therapy is structured and standardizes the procedures that are used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. Each of the eight sessions, as well as the homework to be completed in between sessions, is described in detail to help clinicians implement the treatment and maintain consistency. Handouts for each session are also included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11079120\">",
"    <span class=\"h2\">",
"     Clinician training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prerequisites for leading mindfulness-based cognitive therapy groups is that the clinician practices mindfulness meditation and attends training workshops [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. This limits the treatment&rsquo;s availability, but is intended to control its quality; our experience is that the poorest outcomes seem to result from clinicians teaching mindfulness without practicing it themselves. During mindfulness meditation, patients encounter difficulties or confusion about what is expected. Clinicians who have not experienced these challenges appear less able to help patients manage them and continue treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5,33\">",
"     5,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H545232\">",
"    <span class=\"h2\">",
"     Combined with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is compatible with maintenance pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/11,12,14\">",
"     11,12,14",
"    </a>",
"    ]. If the two treatments are provided by different clinicians, they need to work together as members of the same treatment team. This should include an agreement with each other and the patient that the two clinicians will share any concerns they have and not keep secrets. Patients commonly tell the clinician providing mindfulness based cognitive therapy that they wish to discontinue their antidepressants; these patients should be redirected to the clinician prescribing the medication. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2077158\">",
"    <span class=\"h2\">",
"     Format",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy is a group program consisting of eight weekly sessions, each lasting two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5,34\">",
"     5,34",
"    </a>",
"    ]. The group typically includes 8 to 15 patients. The skills learned during the sessions are practiced daily in between sessions for up to one hour.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H259630147\">",
"    <span class=\"h2\">",
"     Therapeutic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each session focuses upon learning mindfulness meditation and CBT concepts and skills within a group setting.",
"   </p>",
"   <p>",
"    Meditation and other practices are used to develop mindfulness, ie, purposeful attention to the present moment. Patients learn to observe their thoughts, feelings, and bodily sensations with curiosity and without criticizing themselves or passing judgement upon what is observed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. Sitting meditation often focuses upon breathing and the sensations of respiration. Another mindfulness practice is the body scan, which involves paying attention to different parts of the body and noticing any tension, pain, bracing, or numbing. Mindfulness is also practiced while patients stretch or walk. Each of these practices typically last for 40 minutes, but others are shorter (eg, Three-Minute Coping Breathing Space, a technique for managing rumination about a problem, and the Three-Minute Breathing Space, a technique for connecting with the present moment). In addition, mindfulness is practiced with everyday activities such as eating.",
"   </p>",
"   <p>",
"    Mindfulness based cognitive therapy makes use of CBT techniques that include prescribing homework and teaching patients about depressive symptoms, dysfunctional thoughts that frequently accompany depression, and how thoughts can affect the emotional impact of an event [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. The clinician also describes the CBT model of thoughts and feelings (ABC: Antecedent, Behavior, and Consequence). In addition, patients create a behavior plan to prevent relapse, which includes a list of both activating, pleasurable activities and habitual dysfunctional thoughts, as well as a letter that the patient addresses to",
"    <span class=\"nowrap\">",
"     him/herself",
"    </span>",
"    explaining the importance of staying active, reducing self-criticism, and giving oneself credit for successes.",
"   </p>",
"   <p>",
"    The group format provides several therapeutic benefits, including mutual support and decreased isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, patients learn from each other as they discuss their struggles with depression and dysfunctional thoughts, and their difficulties with developing attentional focus.",
"   </p>",
"   <p>",
"    The last session addresses termination. The clinician asks patients to speak candidly about what they have learned, encourages them to practice mindfulness after the group meetings stop, and helps patients say goodbye [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the clinician gives each patient a small object, such as a marble or small polished stone, to remind patients of the other group members and their shared emotional experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2077024\">",
"    <span class=\"h2\">",
"     Managing clinical deterioration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If depressive symptoms recur during mindfulness based cognitive therapy, the clinician should assess the patient outside of the group setting to determine whether and how the treatment plan should be modified. If clinical deterioration occurs because the patient misses group sessions or does not complete homework assignments, the clinician and patient should decide whether the patient can recommit to the treatment, or whether alternative treatment is indicated. Alternative treatment may also be indicated if the patient is adhering to mindfulness-based cognitive therapy but is not responding; options include adding pharmacotherapy, or switching to pharmacotherapy or a different psychotherapy such as interpersonal psychotherapy. Another option is to join a new mindfulness-based cognitive therapy group after the patient has improved with alternative treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for continuing mindfulness based cognitive therapy for patients with subsyndromal symptoms comes from a randomized trial that compared mindfulness-based cognitive therapy with placebo pill [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/15\">",
"     15",
"    </a>",
"    ]. Some patients suffered symptoms that did not meet full criteria for major depression; these symptoms were less likely to progress to a full-blown episode in patients receiving therapy. In another study, mindfulness-based cognitive therapy may have improved residual depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26977547\">",
"    <span class=\"h1\">",
"     CONTINUING CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of mindfulness based cognitive therapy is to teach skills that patients will use beyond treatment termination. The risk for recurrence of major depression persists for years after recovery from an episode [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/36\">",
"     36",
"    </a>",
"    ], and patients are thus encouraged to practice mindfulness indefinitely (much as hypertensive patients are vigilant for high-sodium foods). Several resources are available to support the ongoing practice of mindfulness. (See",
"    <a class=\"local\" href=\"#H2241279\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, some programs include monthly follow-up sessions (&ldquo;graduate classes&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/18\">",
"     18",
"    </a>",
"    ]. These sessions typically include a 30 minute sitting meditation focusing upon the breath, along with 30 minutes of mindful stretching or walking. The discussion afterwards addresses the challenges of practicing mindfulness, with less emphasis on therapeutic problem solving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26977554\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness based cognitive therapy has primarily been used to delay or prevent recurrences of unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. In addition, the therapy may also reduce residual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17845362\">",
"    <span class=\"h2\">",
"     Preventing recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized maintenance trials suggest that for euthymic patients with a history of at least three major depressive episodes, mindfulness-based cognitive therapy may possibly delay or prevent recurrence of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. A meta-analysis of five randomized trials (358 euthymic patients with at least three major depressive episodes) that compared mindfulness-based cognitive therapy with a control condition found that relapse occurred in fewer patients who received active treatment (36 versus 63 percent); there was no evidence of heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/37\">",
"     37",
"    </a>",
"    ]. Trials that evaluated the therapy in patients with only two prior episodes found that it was not beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studying the efficacy of mindfulness based cognitive therapy, no trials have addressed the relative contribution of mindfulness mediation and the cognitive-behavioral therapy techniques, or compared mindfulness-based cognitive therapy with a different psychotherapy.",
"   </p>",
"   <p>",
"    Psychotherapy trials, like pharmacotherapy trials, are methodologically variable. Rigorous psychotherapy trials specify a priori hypotheses and analytic tests, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, carefully blind outcome ratings, develop manuals for the psychotherapies that are studied and measure the clinician&rsquo;s adherence, and stratify patients on predetermined risk variables. Less meticulous studies use open-label designs, less rigorous comparators (eg, treatment as usual or waiting lists), or fail to adequately blind outcome ratings. Although it is commonly believed that blinding of patients in psychotherapy trials is less successful compared with pharmacotherapy trials, this has never been studied.",
"   </p>",
"   <p>",
"    Meta-analyses appear to overestimate the clinical effect of nearly all psychotherapies that are used to treat depression because of publication bias and study quality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5751098\">",
"    <span class=\"h3\">",
"     Mindfulness based cognitive therapy alone compared with pharmacotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness-based cognitive therapy may be as effective as medication for maintenance treatment of unipolar major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A meta-analysis of two randomized trials (177 euthymic patients with at least three major depressive episodes) that compared mindfulness-based cognitive therapy with antidepressant medication found that relapse was comparable for the two groups (45 and 56 percent of patients); there was no evidence of heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2240063\">",
"    <span class=\"h3\">",
"     Mindfulness based cognitive therapy plus treatment as usual compared with treatment as usual alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance treatment with mindfulness based cognitive therapy plus treatment as usual may possibly be more effective than treatment as usual alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. A meta-analysis examined four randomized trials (326 patients in remission from unipolar major depression) that compared combination treatment with treatment as usual alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29\">",
"     29",
"    </a>",
"    ]. The trials either required a history of at least three depressive episodes, or stratified for randomization based upon number of prior episodes (two versus more than two) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Treatment as usual consisted of instructions for patients to contact their primary care or mental health clinician if symptomatic deterioration occurred. The meta-analysis found that for patients with a history of at least three depressive episodes, relapse occurred in fewer patients who received the combination compared with treatment as usual alone (32 versus 60 percent); heterogeneity was mild to moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29\">",
"     29",
"    </a>",
"    ]. However, this benefit may have resulted from differences in the treatment as usual that each group received (pharmacotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychotherapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In addition, it&rsquo;s not clear whether mindfulness based cognitive therapy provided any specific effects because the randomized trials did not control for the additional attention it conferred [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the meta-analysis found that for patients with only two prior episodes of major depression (total of 50 patients), adding mindfulness based cognitive therapy to treatment as usual provided no additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/29\">",
"     29",
"    </a>",
"    ]. The small number of patients with two episodes and the lower rate of recurrence in patients with a more benign history probably contributed to this finding, although it is possible that patients with a history of two episodes do not derive the same benefit as do patients with at least three episodes.",
"   </p>",
"   <p>",
"    A subsequent eight week randomized trial compared mindfulness-based cognitive therapy plus treatment as usual with treatment as usual alone in 205 patients with three or more prior episodes of unipolar major depression (66 percent had recovered from their most recent episode, 34 percent were still symptomatic) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/2\">",
"     2",
"    </a>",
"    ]. There were significantly fewer depressive symptoms at the end of treatment in patients who received mindfulness-based cognitive therapy, and results were comparable for euthymic patients and patients with depressive symptoms at study entry. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3087466\">",
"    <span class=\"h4\">",
"     Mindfulness based cognitive therapy plus pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients receive mindfulness based cognitive therapy plus pharmacotherapy as maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/11,12,14\">",
"     11,12,14",
"    </a>",
"    ]. However, it is not known whether combination treatment is beneficial, because no randomized trials have compared mindfulness-based cognitive therapy alone, pharmacotherapy alone, and their combination. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17845393\">",
"    <span class=\"h2\">",
"     Resolving residual symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residual depressive symptoms are a risk factor for recurrence of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/41\">",
"     41",
"    </a>",
"    ]; mindfulness-based cognitive therapy may reduce residual symptoms, regardless of the number of prior episodes of major depression. An eight week, open label, randomized trial compared mindfulness based cognitive therapy plus treatment as usual with treatment as usual (waiting list) alone in 130 patients who no longer met criteria for major depression, but still suffered residual symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/20\">",
"     20",
"    </a>",
"    ]. Randomization was stratified, based upon number of prior episodes (one or two versus three or more). Improvement of residual symptoms was greater in patients who received mindfulness based cognitive therapy, regardless of the number of prior episodes. In addition, the improvement persisted for 12 months. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Books, compact disks, and websites devoted to mindfulness meditation are available to augment mindfulness-based cognitive therapy. A handbook is available for patients enrolled in mindfulness-based cognitive therapy or patients deciding whether it is suitable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/3\">",
"     3",
"    </a>",
"    ]. A website also describes the intervention and includes links to programs in North America and Europe as well as research papers that can be downloaded [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8584/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26977561\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mindfulness based cognitive therapy is a skills-training group program that is used to delay or prevent recurrence of major depression. The therapy combines the clinical application of mindfulness meditation with elements of cognitive-behavioral therapy (CBT). (See",
"      <a class=\"local\" href=\"#H26977519\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26977526\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mindfulness based cognitive therapy is indicated for maintenance treatment of euthymic patients who have suffered at least three episodes of unipolar major depression. In addition, the therapy may reduce residual depressive symptoms, regardless of the number of prior episodes of major depression. The therapy can be used alone or in conjunction with pharmacotherapy. The treatment is contraindicated for patients with impaired attention and concentration, active suicidal ideation and no other current maintenance treatment, or a history of untreated trauma. (See",
"      <a class=\"local\" href=\"#H2239853\">",
"       'Indication'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2240511\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mindfulness is purposeful, nonjudgmental attention to the thoughts and feelings that occur each moment. CBT is based upon the theory that maladaptive thoughts and behaviors lead to psychopathology; the clinician addresses these dysfunctional cognitions and the patient tries to change the resulting problematic behaviors. (See",
"      <a class=\"local\" href=\"#H26977526\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should assess the prospective patient&rsquo;s current clinical status, prior course of illness, and commitment to attend the eight two-hour weekly sessions and complete the daily homework. (See",
"      <a class=\"local\" href=\"#H26977533\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mindfulness based cognitive therapy interventions include meditation, the body scan, and mindfulness while stretching or walking. The therapy also uses some CBT techniques, which include learning about depressive symptoms and dysfunctional thoughts, and creating a behavior plan to prevent relapse. (See",
"      <a class=\"local\" href=\"#H259630147\">",
"       'Therapeutic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials suggest that for euthymic patients with a history of at least three unipolar major depressive episodes, mindfulness based cognitive therapy may possibly delay or prevent recurrence. In addition, the therapy may improve residual depressive symptoms. (See",
"      <a class=\"local\" href=\"#H26977554\">",
"       'Evidence of efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/1\">",
"      Segal ZV, Kennedy S, Gemar M, et al. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse. Arch Gen Psychiatry 2006; 63:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/2\">",
"      van Aalderen JR, Donders AR, Giommi F, et al. The efficacy of mindfulness-based cognitive therapy in recurrent depressed patients with and without a current depressive episode: a randomized controlled trial. Psychol Med 2012; 42:989.",
"     </a>",
"    </li>",
"    <li>",
"     Williams, JM, Teasdale, JD, Segal, ZV, Kabat-Zinn, J. The mindful way through depression: Freeing yourself from chronic unhappiness, Guilford Press, New York 2007.",
"    </li>",
"    <li>",
"     Beck, AT, Rush, AJ, Shaw, BF, Emery, G. Cognitive therapy of depression, Guilford Press, New York 1979.",
"    </li>",
"    <li>",
"     Segal ZV, Williams JMG, Teasdale JD. Mindfulness Based Cognitive Therapy for Depression, Guilford Press, New York 2013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/6\">",
"      Chiesa A, Calati R, Serretti A. Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clin Psychol Rev 2011; 31:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/7\">",
"      Farb NA, Anderson AK, Mayberg H, et al. Minding one's emotions: mindfulness training alters the neural expression of sadness. Emotion 2010; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/8\">",
"      Chiesa A, Serretti A. A systematic review of neurobiological and clinical features of mindfulness meditations. Psychol Med 2010; 40:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/9\">",
"      H&ouml;lzel BK, Carmody J, Vangel M, et al. Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Res 2011; 191:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/10\">",
"      H&ouml;lzel BK, Carmody J, Evans KC, et al. Stress reduction correlates with structural changes in the amygdala. Soc Cogn Affect Neurosci 2010; 5:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/11\">",
"      Teasdale JD, Segal ZV, Williams JM, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000; 68:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/12\">",
"      Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004; 72:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/13\">",
"      Bondolfi G, Jermann F, der Linden MV, et al. Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system. J Affect Disord 2010; 122:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/14\">",
"      Godfrin KA, van Heeringen C. The effects of mindfulness-based cognitive therapy on recurrence of depressive episodes, mental health and quality of life: A randomized controlled study. Behav Res Ther 2010; 48:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/15\">",
"      Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Arch Gen Psychiatry 2010; 67:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/16\">",
"      Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008; 76:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/17\">",
"      Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 2009; 117 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     Depression: The treatment and management of depression in adults. NICE clinical guideline 90. Issued October, 2009. file://guidance.nice.org.uk/CG90/NICEGuidance/pdf/English (Accessed on March 30, 2011).",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. Published October, 2010. file://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx (Accessed on March 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/20\">",
"      Geschwind N, Peeters F, Huibers M, et al. Efficacy of mindfulness-based cognitive therapy in relation to prior history of depression: randomised controlled trial. Br J Psychiatry 2012; 201:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/21\">",
"      Teasdale JD, Cox SG. Dysphoria: self-devaluative and affective components in recovered depressed patients and never depressed controls. Psychol Med 2001; 31:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/22\">",
"      Park RJ, Goodyer IM, Teasdale JD. Self-devaluative dysphoric experience and the prediction of persistent first-episode major depressive disorder in adolescents. Psychol Med 2005; 35:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/23\">",
"      Watkins E, Teasdale JD. Rumination and overgeneral memory in depression: effects of self-focus and analytic thinking. J Abnorm Psychol 2001; 110:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/24\">",
"      Williams JM, Kuyken W. Mindfulness-based cognitive therapy: a promising new approach to preventing depressive relapse. Br J Psychiatry 2012; 200:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/25\">",
"      Teasdale JD, Moore RG, Hayhurst H, et al. Metacognitive awareness and prevention of relapse in depression: empirical evidence. J Consult Clin Psychol 2002; 70:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/26\">",
"      Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. J Consult Clin Psychol 2010; 78:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/27\">",
"      Frewen, PA, Dozois, DJ. Social, achievement, and control factors in personality vulnerability to depression. Cognit Ther Res 2006; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/28\">",
"      Arch JJ, Craske MG. Mechanisms of mindfulness: emotion regulation following a focused breathing induction. Behav Res Ther 2006; 44:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/29\">",
"      Chiesa A, Serretti A. Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res 2011; 187:441.",
"     </a>",
"    </li>",
"    <li>",
"     Segal, Z, Williams, JM, Teasdale, JD. Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse, Guilford Press, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/31\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/32\">",
"      Kroenke, K, Spitzer, RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Annals 2002; 32:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/33\">",
"      Grepmair L, Mitterlehner F, Loew T, et al. Promoting mindfulness in psychotherapists in training influences the treatment results of their patients: a randomized, double-blind, controlled study. Psychother Psychosom 2007; 76:332.",
"     </a>",
"    </li>",
"    <li>",
"     Coffman SJ, Dimidjian S, Baer RA. Mindfulness-Based Cognitive Therapy for Prevention of Depressive Relapse. In: Mindfulness-Based Treatment Approaches: Clinician's Guide to Evidence Base and Applications, Baer RA.  (Ed), Elsevier, Burlington, MA 2006. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/35\">",
"      Kingston T, Dooley B, Bates A, et al. Mindfulness-based cognitive therapy for residual depressive symptoms. Psychol Psychother 2007; 80:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/36\">",
"      Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/37\">",
"      Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev 2011; 31:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/38\">",
"      Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2010; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/39\">",
"      Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 2010; 196:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/40\">",
"      Coelho HF, Canter PH, Ernst E. Mindfulness-based cognitive therapy: evaluating current evidence and informing future research. J Consult Clin Psychol 2007; 75:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8584/abstract/41\">",
"      Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     Mindfulness-Based Cognitive Therapy file://www.mbct.com/ (Accessed on April 07, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14682 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8584=[""].join("\n");
var outline_f8_24_8584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26977561\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977519\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2239853\">",
"      INDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2240511\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977526\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977533\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977540\">",
"      DELIVERING MINDFULNESS BASED COGNITIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11079120\">",
"      Clinician training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H545232\">",
"      Combined with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2077158\">",
"      Format",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H259630147\">",
"      Therapeutic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2077024\">",
"      Managing clinical deterioration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977547\">",
"      CONTINUING CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977554\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17845362\">",
"      Preventing recurrences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5751098\">",
"      - Mindfulness based cognitive therapy alone compared with pharmacotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2240063\">",
"      - Mindfulness based cognitive therapy plus treatment as usual compared with treatment as usual alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3087466\">",
"      Mindfulness based cognitive therapy plus pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17845393\">",
"      Resolving residual symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26977561\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14682|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/19/36157\" title=\"table 1\">",
"      Mindfulness-based cognitive therapy handout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 2\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_24_8585="Supportive data for advanced cardiac life support in adults with sudden cardiac arrest";
var content_f8_24_8585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Charles N Pozner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Richard L Page, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/24/8585/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/24/8585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, often due to sustained ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation. Other causes of SCA and SCD are asystole and pulseless electrical activity. These events most commonly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of SCA consists of emergent resuscitation followed, in survivors, by immediate postresuscitative care and attempted long-term prevention of recurrence using pharmacologic and nonpharmacologic means. Over time, cardiopulmonary resuscitation (CPR) performed by bystanders has increased, and the interval between collapse and defibrillation has decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Despite these improvements as well as advances in the treatment of heart disease, the outcome of patients experiencing SCA remains poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data supporting advanced cardiac life support (ACLS) recommendations for the management of SCA will be reviewed here. The performance of ACLS, controversies surrounding cardiopulmonary resuscitation, and issues related to the prevention of recurrent SCA in survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=see_link\">",
"     \"Therapies of uncertain benefit in basic and advanced cardiac life support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VF AND PULSELESS VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT) is the same (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 1",
"    </a>",
"    ). Survival depends upon prompt, successful defibrillation to reestablish organized electrical activity with a stable sinus or supraventricular rhythm, as well as excellent cardiopulmonary resuscitation (CPR) with chest compressions. CPR should be provided throughout the resuscitative effort; pauses should only occur at two-minute intervals for rhythm analysis and defibrillation. Other procedures, such as advanced airway management or vascular access, should not be performed in the initial resuscitation efforts (ie, first few minutes), and then should be performed during active CPR or should be attempted during the pauses for possible defibrillation. Attempts at these procedures should be brief and should never create prolonged delays in resumption of CPR. Assessment for return of spontaneous circulation should not occur during the two-minute periods of CPR, and when performed, should be kept as brief as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific issues relating to the management of VF and pulseless VT, including technical aspects of defibrillation, are discussed below. The use of automated external defibrillators (AED) for the treatment of cardiac arrest is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only effective approach for the treatment of VF is defibrillation. VF rarely, if ever, terminates spontaneously or after delivery of an antiarrhythmic drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link&amp;anchor=H17#H17\">",
"     \"Cardioversion for specific arrhythmias\", section on 'Ventricular fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of defibrillation and patient survival depends upon the duration of the arrhythmia and the promptness of defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When VF has been present for seconds to a few minutes and the fibrillatory waves are coarse, the success rate for terminating VF with defibrillation is high.",
"     </li>",
"     <li>",
"      As VF continues for a longer period of time, the fibrillatory waves become finer (",
"      <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"       waveform 1",
"      </a>",
"      ), and the ability to terminate the arrhythmia is reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When VF continues for more than four minutes, even if accompanied by excellent CPR, irreversible damage to the central nervous system and other organs begins, which can reduce survival even if defibrillation is successful&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is strong evidence that a shorter duration between cessation of compressions and delivery of defibrillation is related to increased defibrillation success [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In a prospective observational cohort of 506 adult patients with out-of-hospital cardiac arrest, patients with the highest chest compression fractions (61 to 80 percent and 81 to 100 percent), defined as the proportion of time in cardiac arrest without spontaneous circulation during which chest compressions were being performed, had the greatest chance of survival to hospital discharge (adjusted odds ratios 3.01, 95% CI 1.37-6.58 and 2.33, 95% CI 0.96-5.63 respectively). Defibrillators should be fully charged prior to cessation of compressions, after which immediate rhythm identification and shock delivery is performed as indicated (this should typically occur in no more than three to five seconds).",
"   </p>",
"   <p>",
"    In a series of over 12,000 patients treated by Emergency Medical Services, 4546 had witnessed VF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/2\">",
"     2",
"    </a>",
"    ]. For these patients with witnessed VF, a shorter defibrillation response interval was significantly correlated with an increased chance of survival to hospital discharge. The analysis yielded an odds ratio for survival of 0.88 for every one-minute increase in response time, which corresponds to a 3 to 5 percent drop in survival for each minute of delay to defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes may be improved by performing CPR before defibrillation. This was illustrated in a report that compared outcomes in patients with out-of-hospital VF in two time periods: when an initial shock was given as soon as possible; and when the initial shock was delayed until 90 seconds of CPR had been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/14\">",
"     14",
"    </a>",
"    ]. Survival to hospital discharge was significantly increased with routine CPR before defibrillation (30 versus 24 percent without prior CPR); this benefit was primarily seen in patients in whom the initial response interval was four minutes or longer (27 versus 17 percent without prior CPR).",
"   </p>",
"   <p>",
"    The benefit of prior CPR was confirmed in a subsequent randomized controlled trial in which 200 patients presenting with out-of-hospital VF were assigned to immediate defibrillation or CPR for three minutes prior to the first defibrillation attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/15\">",
"     15",
"    </a>",
"    ]. There was no difference in outcome between the two groups for patients with an EMS response time &le;5 minutes. For those with response times &gt;5 minutes, patients undergoing CPR first were significantly more likely to survive to hospital discharge (22 versus 4 percent). Subsequent randomized controlled studies, however, have not confirmed that performing CPR prior to defibrillation improves survival to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further discussion on the timing of defibrillation and its impact on outcomes in patients with sudden cardiac arrest is presented separately.",
"   </p>",
"   <p>",
"    Based upon the above studies, the 2010 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation and emergency cardiovascular care suggest the initiation of CPR while awaiting the arrival of a defibrillator [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Once the defibrillator is attached to the patient, CPR should be briefly stopped to allow for a rhythm check and shock if indicated (cessation of compressions should not occur until the defibrillator is fully charged), followed by immediate resumption of CPR for two minutes prior to any additional rhythm checks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Defibrillatory waveforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillators manufactured prior to 2000 deliver a monophasic wave of direct electrical current. Since then, \"biphasic\" devices have been developed, which reverse current polarity 5 to 10 milliseconds after discharge begins (",
"    <a class=\"graphic graphic_figure graphicRef51842 \" href=\"UTD.htm?23/36/24140\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Biphasic waveforms defibrillate more effectively and at lower energies than monophasic waveforms. They have a much higher likelihood of first shock efficacy, which is the basis for the change in the guidelines from a prior recommendation of three shocks to a single shock. Data comparing the use of monophasic and biphasic waveforms in the treatment of VF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H11#H11\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Monophasic versus biphasic waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     VF or VT arrest and vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite limited data, the 2010 AHA guidelines concluded that it is appropriate to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (1 mg intravenously every three to five minutes) for patients presenting with cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/21\">",
"     21",
"    </a>",
"    ]. Routine use of high-dose epinephrine is not supported by data and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a prospective observational study of 417,188 adults with out-of-hospital cardial arrest, investigators compared return of spontaneous circulation (ROSC), survival, and neurologic outcome in patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (15,030 patients, 3.6 percent) with those who did not receive epinephrine (402,158 patients, 96.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/24\">",
"     24",
"    </a>",
"    ]. While there was a significantly greater ROSC in the epinephrine group (18.5 versus 5.7 percent using raw data, 18.3 versus 10.5 percent using propensity analysis), this did not translate into improved outcomes. In fact, using propensity analysis, patients receiving epinephrine had significantly lower rates of survival at one month (5.1 versus 7.0 percent), survival with moderate or good cerebral performance (1.3 versus 3.1 percent), and survival with no, mild, or moderate neurological disability (1.3 versus 3.1 percent). Although this study is limited by its observational nature, the results call into question the routine use of epinephrine in the treatment of out-of-hospital cardiac arrest and should serve as an impetus for randomized controlled trials of this issue.",
"   </p>",
"   <p>",
"    The 2010 AHA guidelines concluded that a single dose of 40 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    may be administered in place of the first or second dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in the treatment of a VF or pulseless VT arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, clear evidence that this approach is superior to epinephrine is lacking. Although a single randomized controlled trial found higher rates of successful resuscitation and 24-hour survival with vasopressin compared to epinephrine, subsequent randomized trials and a meta analysis failed to show an improvement in initial ROSC or survival to hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Furthermore, in a multicenter trial of 1442 patients, treatment of out-of-hospital cardiac arrest with a combination of epinephrine and vasopressin did not improve outcomes compared to treatment with epinephrine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because vasopressors given in the setting of ROSC may be detrimental, it is now strongly suggested that resuscitation be performed using quantitative waveform capnography so that ROSC may be more readily identified during ongoing compressions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H4318336#H4318336\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Airway management during ACLS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not uncommon for ventricular fibrillation (VF) or ventricular tachycardia (VT) to persist despite defibrillation or to recur promptly after successful defibrillation. The 2010 AHA guidelines state that intravenous antiarrhythmic drug therapy may be used in such cases, although benefit from this therapy remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20,33\">",
"     19,20,33",
"    </a>",
"    ]. Antiarrhythmic drugs that may be used include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , with amiodarone as the preferred agent. The performance of ACLS, including the details of antiarrhythmic drug therapy, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    increases ROSC and survival to hospital admission compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    in patients with refractory VF and pulseless VT, although its effect on survival to hospital discharge has not been shown.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ALIVE trial of 347 patients with out-of-hospital sudden cardiac arrest (SCA) and persistent or recurrent VF despite three defibrillation shocks, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , and a further attempt at defibrillation, survival to hospital admission was significantly higher in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (23 versus 12 percent for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , odds ratio 2.17, 95% CI 1.21-3.83) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/34\">",
"       34",
"      </a>",
"      ]. Among patients who had the return of spontaneous circulation prior to antiarrhythmic administration, amiodarone led to an even higher rate of survival to admission (42 versus 27 percent with lidocaine).",
"      <br/>",
"      <br/>",
"      Despite these benefits, the in-hospital death rates in the two groups were 78 and 75 percent, similar to those in other studies, and there was no significant difference in survival to hospital discharge (nine and five patients in the amiodarone and lidocaine groups, respectively). These results are not surprising given the prolonged duration of the cardiac arrest.",
"     </li>",
"     <li>",
"      In the ARREST trial of 504 patients with SCA due to VF or pulseless VT who were not resuscitated after at least three defibrillation shocks, patients were randomly assigned to intravenous bolus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (300 mg) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/35\">",
"       35",
"      </a>",
"      ]. While the mean time to resuscitation and the total number of shocks delivered were similar in the two groups, survival to hospital admission was significantly greater in the amiodarone group (44 versus 34 percent with placebo), especially in patients who had the return of spontaneous circulation during defibrillation prior to receiving amiodarone (64 versus 41 percent placebo). Amiodarone, however, was associated with more adverse effects, including hypotension (59 versus 48 percent) and bradycardia requiring therapy (41 versus 25 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The ARREST trial was not sufficiently powered to detect differences in survival to hospital discharge, which did not differ significantly between the two groups, similar to the findings in the ALIVE trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is also effective for the acute suppression of life-threatening, hemodynamically significant ventricular tachyarrhythmias that recur despite therapy with other agents. Amiodarone can prevent recurrence of sustained spontaneous VT or VF in more than 50 percent of patients, and it has been approved for the acute treatment and prevention of VF and for hemodynamically significant VT that is refractory to other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    has been found to be less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    for the treatment of SCA caused by VF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/34\">",
"     34",
"    </a>",
"    ]. The 2010 AHA guidelines state that amiodarone is the first-line antiarrhythmic agent during cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Amiodarone'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H3328729#H3328729\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Sudden cardiac arrest'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from randomized trials do NOT support the routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    for the treatment of cardiac arrest. However, observational data from a small number of patients suggest that intravenous magnesium sulfate is beneficial for the treatment of a VF or pulseless VT arrest due to drug-induced prolonged QT interval associated with torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/38\">",
"     38",
"    </a>",
"    ]. The 2010 AHA guidelines state that this is the only arrhythmia for which administration of magnesium sulfate should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Torsades de pointes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Induced hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The induction of mild to moderate hypothermia (target temperature 32 to 34&ordm;C for 24 hours) has been shown to be beneficial in patients successfully resuscitated after a cardiac arrest who are comatose. Improved neurologic outcome and reduced mortality have been demonstrated in multiple series of patients with VF arrest in whom spontaneous circulation was restored, even when the patient remained comatose after resuscitation. Induced hypothermia is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H18#H18\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Post-resuscitation care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Therapeutic (induced) hypothermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PULSELESS ELECTRICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to ventricular fibrillation or pulseless ventricular tachycardia, there is no role for defibrillation in the management of pulseless electrical activity (PEA) or asystole (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 1",
"    </a>",
"    ). Excellent cardiopulmonary resuscitation (CPR) and vasopressor therapy should be provided. However, the prompt identification of reversible causes while minimizing delays in CPR is the mainstay of treatment of PEA (",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"     table 1",
"    </a>",
"    ). Reversible causes include the five H's and T's (hypoxia, hypovolemia, hydrogen ion (acidosis),",
"    <span class=\"nowrap\">",
"     hypo-/hyperkalemia,",
"    </span>",
"    hypothermia, toxins [especially narcotics and benzodiazepines], tamponade [cardiac], tension pneumothorax, thrombosis [pulmonary], thrombosis [coronary]) as defined by the 2010 AHA guidelines. While CPR with excellent chest compressions is performed, other rescuers should not be afraid to perform \"heroic\" procedures if indicated for an identified reversible cause of PEA.",
"   </p>",
"   <p>",
"    CPR should be provided throughout the resuscitative effort, except during brief pauses at two-minute intervals to analyze the rhythm and assess for return of spontaneous circulation. In a cohort of 3960 patients with out-of-hospital cardiac arrest and a non-shockable cardiac rhythm, 1774 patients were treated with ACLS before and 2186 patients were treated with ACLS after the revised 2005 guidelines, which increased the emphasis on chest compressions during resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients treated after 2005 with an increased emphasis on chest compressions had significantly greater return of spontaneous circulation (34 versus 27 percent), one month survival (6.2 versus 4.1 percent), and favorable neurologic outcomes (5.1 versus 3.4 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H9#H9\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Asystole and pulseless electrical activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     PEA and vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (1 mg intravenous push every three to five minutes) for PEA remains uncertain, but it remains a part of the 2010 AHA guidelines for the treatment of cardiac arrest with PEA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20,24\">",
"     19,20,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'VF or VT arrest and vasopressors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several of the studies comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in cardiac arrest enrolled patients with PEA. Since neither agent was found to be superior, the 2010 AHA guidelines allow for the substitution of a single dose of 40 units of vasopressin for the first or second dose of epinephrine, as with a VF or pulseless VT arrest. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'VF and pulseless VT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     PEA and atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 AHA guidelines have removed the routine administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    in the setting of PEA from the treatment algorithm due to its lack of therapeutic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The administration of atropine (1 mg every three to five minutes) may be considered for PEA when the rate is slow, ie, absolute bradycardia with a rate &lt;50",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or a relative bradycardia (rate less than expected relative to the underlying condition).",
"   </p>",
"   <p>",
"    In a cohort study of 1029 patients with PEA published after the 2010 AHA guidelines, 30-day neurologic outcomes were no different in the groups treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    versus epinephrine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, survival was significantly lower in the group treated with epinephrine and atropine (3.2 percent versus 7.1 percent in epinephrine only group; odds ration 0.43, 95% CI 0.19 to 0.91), suggesting that atropine may actually be harmful when used to treat PEA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ASYSTOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest in which asystole is the initial rhythm is associated with an extremely poor prognosis (0 to 2 percent survival to hospital discharge). Asystole is usually a secondary event, resulting from ventricular fibrillation (VF) or pulseless electrical activity (PEA) which has been present for several minutes or longer with subsequent loss of all electrical activity. It may also occur as a result of prolonged hypoxia, acidosis, and death of myocardial tissue (",
"    <a class=\"graphic graphic_waveform graphicRef67777 \" href=\"UTD.htm?26/1/26648\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link&amp;anchor=H4#H4\">",
"     \"Outcome of sudden cardiac arrest\", section on 'Asystole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    True asystole should be confirmed by checking the defibrillator cable connections, making certain that the gain is turned up and the monitor is working, and confirming asystole in another lead. The 2010 AHA guidelines recommend that asystole be treated in the same manner as PEA, with excellent cardiopulmonary resuscitation (CPR), vasopressors, and the consideration of possible reversible causes (",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    is no longer recommended as therapy in asystole. CPR, with an emphasis on adequate chest compression, should be provided throughout the resuscitative effort, except at two-minute intervals during which brief pauses to analyze the rhythm and assess for return of spontaneous circulation can take place [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/39\">",
"     39",
"    </a>",
"    ]. There is no benefit to defibrillation in patients with asystole. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pulseless electrical activity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H9#H9\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Asystole and pulseless electrical activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because randomized controlled trials and other data have not shown a survival benefit with the use of temporary pacing in asystole, its routine use is not recommended by the 2010 AHA guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/41-45\">",
"     41-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged resuscitative efforts of patients in asystole are generally futile. Termination of resuscitation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H19#H19\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Termination of resuscitative efforts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Asystole and vasopressors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    (1 mg intravenous push every three to five minutes) is recommended in patients with asystole, although its benefit has not been clearly demonstrated in prospective trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20,24\">",
"     19,20,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'VF or VT arrest and vasopressors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Routine use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    is not supported by data and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a randomized trial comparing repeated high doses and standard doses of epinephrine for out-of-hospital cardiac arrest, survival to hospital discharge was similar with high-dose and standard dose epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/23\">",
"     23",
"    </a>",
"    ]. Although high-dose epinephrine improved the rate of successful resuscitation in patients with asystole, it did not improve survival to hospital discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Vasopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     Vasopressin",
"    </a>",
"    has been studied as a potential alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    . In one trial comparing vasopressin to epinephrine in 1186 patients with out-of-hospital arrest, the 528 patients with asystole who received vasopressin were significantly more likely to survive until hospital admission (29 versus 20 percent with epinephrine, odds ratio 0.6, 95% CI 0.4-0.9) and hospital discharge (4.7 versus 1.5 percent, odds ratio 0.3, 95% CI 0.1-1.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/27\">",
"     27",
"    </a>",
"    ]. However, a subsequent meta-analysis, which included data from this and four smaller studies (1519 patients overall), found no significant benefit of vasopressin compared to epinephrine among patients with asystole, or any other initial cardiac rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these data, the guidelines allow for a single dose of 40 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    to be substituted for the first or second dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in patients with asystole, as with PEA or a VF and pulseless VT arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Asystole and atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to a paucity of data supporting the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    for asystole, the 2010 AHA guidelines no longer recommend the routine use of atropine for the management of asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a cohort study of 6419 patients with asystole published after the 2010 AHA guidelines, return of spontaneous circulation was significantly greater in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and atropine (33 versus 19 percent with epinephrine alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/24/8585/abstract/40\">",
"     40",
"    </a>",
"    ]. However, overall survival and 30-day neurologic outcomes were no different in the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INEFFECTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of therapies have been shown to be generally ineffective in patients who present with sudden cardiac arrest, and therefore are not part of routine management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      , except in patients with hyperkalemia (calcium is first-line therapy) or tricyclic antidepressant overdose",
"     </li>",
"     <li>",
"      Fibrinolytic therapy",
"     </li>",
"     <li>",
"      Cardiac pacing for asystole or pulseless electrical activity",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      , except in patients who have drug-induced QT prolongation and develop torsades de pointes (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Magnesium sulfate'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relevant data regarding these therapies are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=see_link\">",
"     \"Therapies of uncertain benefit in basic and advanced cardiac life support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13805962\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with sudden cardiac arrest (SCA), survival depends upon prompt resuscitative efforts, including excellent cardiopulmonary resuscitation (CPR) with chest compressions and, when indicated, defibrillation to reestablish organized electrical activity with a stable rhythm. Chest compressions should not be stopped until the defibrillator is fully charged and the patient is ready for defibrillation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CPR should be provided throughout the resuscitative effort until return of spontaneous circulation or termination of resuscitative efforts. Brief (10 second) pauses in CPR should only occur at two-minute intervals for rhythm analysis and defibrillation, if indicated. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The only definitively effective treatment of ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) is defibrillation, as VF and VT rarely, if ever, terminate spontaneously or after delivery of an antiarrhythmic drug. The chances of successful defibrillation, and survival, are greatest when defibrillation is performed early after the onset of VF or VT. However, while awaiting the arrival and setup of a defibrillator, CPR should be performed. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'VF and pulseless VT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Defibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VF and VT often persist despite defibrillation, or recur promptly after successful defibrillation. In such cases, intravenous antiarrhythmic drug therapy should be used, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      being the preferred antiarrhythmic due to its superior efficacy for the return of spontaneous circulation and survival to hospital admission. Notably in the management of cardiac arrest, amiodarone did not provide any benefit when assessing the clinically relevant outcome of neurologically favorable survival as compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and placebo. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with VF or pulseless VT thought to be due to torsades de pointes with a prolonged QT interval, the administration of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      should be considered. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Magnesium sulfate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to SCA caused by VF or pulseless VT, there is no role for defibrillation in the management of pulseless electrical activity (PEA) or asystole. CPR and vasopressor therapy should be provided, with prompt efforts to identify any reversible causes of PEA or asystole (",
"      <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulseless electrical activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Asystole'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/1\">",
"      Herlitz J, Andersson E, B&aring;ng A, et al. Experiences from treatment of out-of-hospital cardiac arrest during 17 years in G&ouml;teborg. Eur Heart J 2000; 21:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/2\">",
"      Rea TD, Eisenberg MS, Becker LJ, et al. Temporal trends in sudden cardiac arrest: a 25-year emergency medical services perspective. Circulation 2003; 107:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/3\">",
"      Winkle RA, Mead RH, Ruder MA, et al. Effect of duration of ventricular fibrillation on defibrillation efficacy in humans. Circulation 1990; 81:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/4\">",
"      De Maio VJ, Stiell IG, Wells GA, et al. Optimal defibrillation response intervals for maximum out-of-hospital cardiac arrest survival rates. Ann Emerg Med 2003; 42:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/5\">",
"      Larsen MP, Eisenberg MS, Cummins RO, Hallstrom AP. Predicting survival from out-of-hospital cardiac arrest: a graphic model. Ann Emerg Med 1993; 22:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/6\">",
"      Niemann JT, Cairns CB, Sharma J, Lewis RJ. Treatment of prolonged ventricular fibrillation. Immediate countershock versus high-dose epinephrine and CPR preceding countershock. Circulation 1992; 85:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/7\">",
"      Baum RS, Alvarez H 3rd, Cobb LA. Survival after resuscitation from out-of-hospital ventricular fibrillation. Circulation 1974; 50:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/8\">",
"      Callans DJ. Out-of-hospital cardiac arrest--the solution is shocking. N Engl J Med 2004; 351:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/9\">",
"      Thompson RJ, McCullough PA, Kahn JK, O'Neill WW. Prediction of death and neurologic outcome in the emergency department in out-of-hospital cardiac arrest survivors. Am J Cardiol 1998; 81:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/10\">",
"      Eftest&oslash;l T, Sunde K, Steen PA. Effects of interrupting precordial compressions on the calculated probability of defibrillation success during out-of-hospital cardiac arrest. Circulation 2002; 105:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/11\">",
"      Eftestol T, Sunde K, Ole Aase S, et al. Predicting outcome of defibrillation by spectral characterization and nonparametric classification of ventricular fibrillation in patients with out-of-hospital cardiac arrest. Circulation 2000; 102:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/12\">",
"      Eftest&oslash;l T, Wik L, Sunde K, Steen PA. Effects of cardiopulmonary resuscitation on predictors of ventricular fibrillation defibrillation success during out-of-hospital cardiac arrest. Circulation 2004; 110:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/13\">",
"      Christenson J, Andrusiek D, Everson-Stewart S, et al. Chest compression fraction determines survival in patients with out-of-hospital ventricular fibrillation. Circulation 2009; 120:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/14\">",
"      Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA 1999; 281:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/15\">",
"      Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. JAMA 2003; 289:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/16\">",
"      Baker PW, Conway J, Cotton C, et al. Defibrillation or cardiopulmonary resuscitation first for patients with out-of-hospital cardiac arrests found by paramedics to be in ventricular fibrillation? A randomised control trial. Resuscitation 2008; 79:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/17\">",
"      Jacobs IG, Finn JC, Oxer HF, Jelinek GA. CPR before defibrillation in out-of-hospital cardiac arrest: a randomized trial. Emerg Med Australas 2005; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/18\">",
"      Stiell IG, Nichol G, Leroux BG, et al. Early versus later rhythm analysis in patients with out-of-hospital cardiac arrest. N Engl J Med 2011; 365:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/19\">",
"      Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/20\">",
"      Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/21\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/22\">",
"      Brown CG, Martin DR, Pepe PE, et al. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. N Engl J Med 1992; 327:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/23\">",
"      Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated high doses and repeated standard doses of epinephrine for cardiac arrest outside the hospital. European Epinephrine Study Group. N Engl J Med 1998; 339:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/24\">",
"      Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use and survival among patients with out-of-hospital cardiac arrest. JAMA 2012; 307:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/25\">",
"      Lindner KH, Dirks B, Strohmenger HU, et al. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/26\">",
"      Stiell IG, H&eacute;bert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/27\">",
"      Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004; 350:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/28\">",
"      Aung K, Htay T. Vasopressin for cardiac arrest: a systematic review and meta-analysis. Arch Intern Med 2005; 165:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/29\">",
"      Gueugniaud PY, David JS, Chanzy E, et al. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. N Engl J Med 2008; 359:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/30\">",
"      Grmec S, Lah K, Tusek-Bunc K. Difference in end-tidal CO2 between asphyxia cardiac arrest and ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest in the prehospital setting. Crit Care 2003; 7:R139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/31\">",
"      Grmec S, Klemen P. Does the end-tidal carbon dioxide (EtCO2) concentration have prognostic value during out-of-hospital cardiac arrest? Eur J Emerg Med 2001; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/32\">",
"      Kolar M, Krizmaric M, Klemen P, Grmec S. Partial pressure of end-tidal carbon dioxide successful predicts cardiopulmonary resuscitation in the field: a prospective observational study. Crit Care 2008; 12:R115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/33\">",
"      van Walraven C, Stiell IG, Wells GA, et al. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. Ann Emerg Med 1998; 32:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/34\">",
"      Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2002; 346:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/35\">",
"      Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/36\">",
"      Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/37\">",
"      Kowey PR, Levine JH, Herre JM, et al. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/38\">",
"      Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/39\">",
"      Kudenchuk PJ, Redshaw JD, Stubbs BA, et al. Impact of changes in resuscitation practice on survival and neurological outcome after out-of-hospital cardiac arrest resulting from nonshockable arrhythmias. Circulation 2012; 125:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/40\">",
"      Survey of Survivors After Out-of-hospital Cardiac Arrest in KANTO Area, Japan (SOS-KANTO) Study Group. Atropine sulfate for patients with out-of-hospital cardiac arrest due to asystole and pulseless electrical activity. Circ J 2011; 75:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/41\">",
"      Hedges JR, Syverud SA, Dalsey WC, et al. Prehospital trial of emergency transcutaneous cardiac pacing. Circulation 1987; 76:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/42\">",
"      Barthell E, Troiano P, Olson D, et al. Prehospital external cardiac pacing: a prospective, controlled clinical trial. Ann Emerg Med 1988; 17:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/43\">",
"      Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic cardiac arrest. N Engl J Med 1993; 328:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/44\">",
"      Ornato JP, Peberdy MA. The mystery of bradyasystole during cardiac arrest. Ann Emerg Med 1996; 27:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/24/8585/abstract/45\">",
"      Quan L, Graves JR, Kinder DR, et al. Transcutaneous cardiac pacing in the treatment of out-of-hospital pediatric cardiac arrests. Ann Emerg Med 1992; 21:905.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1028 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-5203FA14AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8585=[""].join("\n");
var outline_f8_24_8585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13805962\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VF AND PULSELESS VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Defibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Defibrillatory waveforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VF or VT arrest and vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Induced hypothermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PULSELESS ELECTRICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PEA and vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PEA and atropine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASYSTOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Asystole and vasopressors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Vasopressin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Asystole and atropine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INEFFECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13805962\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1028\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1028|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44022\" title=\"algorithm 1\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1028|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/36/24140\" title=\"figure 1\">",
"      Defibrillation waveforms in ICDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1028|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/18/17708\" title=\"table 1\">",
"      Treatable conditions associated with cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1028|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/1/26648\" title=\"waveform 1\">",
"      ECG showing changes in VF over time",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35448?source=related_link\">",
"      Therapies of uncertain benefit in basic and advanced cardiac life support",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_24_8586="Pseudoporphyria";
var content_f8_24_8586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80856%7EDERM%2F83262%7EDERM%2F83391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80856%7EDERM%2F83262%7EDERM%2F83391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pseudoporphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesiculation and crusting are present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoporphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pseudoporphyria in a patient with vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this patient with vitiligo, bullae developed in areas of pigment loss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8586=[""].join("\n");
var outline_f8_24_8586=null;
var title_f8_24_8587="Glucose challenge test";
var content_f8_24_8587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glucose challenge test for screening for gestational diabetes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Give 50 g oral glucose load without regard to time of day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Measure plasma or serum glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Glucose &ge;130 mg/dL (7.2 mmol/L) or &ge;140 mg/dL (7.8 mmol/L) is elevated and requires administration of a full glucose tolerance test",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The American College of Obstetricians and Gynecologists states that either the 130 mg/dL or 140 mg/dL is an acceptable threshold. The lower threshold provides greater sensitivity but would require administering the full glucose tolerance test to approximately one third more patients than the 140 mg/dL threshold.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American College of Obstetricians and Gynecologists Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001; 98:525.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8587=[""].join("\n");
var outline_f8_24_8587=null;
var title_f8_24_8588="Physiologic effects of high altitude";
var content_f8_24_8588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic effects of high altitude",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High altitude: 1500 to 3500 m (4921-11,483 ft)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-altitude illness common with abrupt ascent to above 2500 m (8202 ft)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased exercise performance and increased ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minor impairment in SpO",
"        <sub>",
"         2",
"        </sub>",
"        , usually at least 90 percent; PaO",
"        <sub>",
"         2",
"        </sub>",
"        significantly diminished 55 to 75 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Very high altitude: 3500 to 5500 m (11,483-18,045 ft)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most common range for severe high-altitude illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abrupt ascent may be dangerous; requires a period of acclimatization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SpO",
"        <sub>",
"         2",
"        </sub>",
"        75 to 85 percent; PaO",
"        <sub>",
"         2",
"        </sub>",
"        40 to 60 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extreme hypoxia may occur during sleep, exercise and high-altitude illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extreme altitude: 5500 to 8850 m (18,045-29,035 ft)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive deterioration of physiologic function eventually outstrips acclimatization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Above the highest permanent human habitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abrupt ascent almost always precipitates severe high-altitude illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A period of acclimatization necessary to ascend to extreme altitude",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe hypoxia and hypocapnia; SpO",
"        <sub>",
"         2",
"        </sub>",
"        58 to 75 percent, PaO",
"        <sub>",
"         2",
"        </sub>",
"        28 to 40 mmHg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SaO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial oxygen saturation; PaO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial PO",
"     <sub>",
"      2",
"     </sub>",
"     ; PO",
"     <sub>",
"      2",
"     </sub>",
"     : partial pressure of oxygen.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hackett, PH, Roach, RC. High-Altitude Medicine. In: Wilderness Medicine, 5th ed, Auerbach, PS (Ed), Mosby, Philadelphia 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8588=[""].join("\n");
var outline_f8_24_8588=null;
var title_f8_24_8589="Case studies of FUO I";
var content_f8_24_8589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Case studies of fever of unknown origin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Author",
"       </td>",
"       <td>",
"        Alt",
"       </td>",
"       <td>",
"        Petersdorf",
"       </td>",
"       <td>",
"        Vanderschueren",
"       </td>",
"       <td>",
"        Miller",
"       </td>",
"       <td>",
"        Knockaert",
"       </td>",
"       <td>",
"        Bleeker-Rovers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Year",
"       </td>",
"       <td>",
"        1913-30",
"       </td>",
"       <td>",
"        1952-59",
"       </td>",
"       <td>",
"        1990-99",
"       </td>",
"       <td>",
"        1989-93",
"       </td>",
"       <td>",
"        1980-89",
"       </td>",
"       <td>",
"        2003-2005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Locale",
"       </td>",
"       <td>",
"        Boston",
"       </td>",
"       <td>",
"        Seattle",
"       </td>",
"       <td>",
"        Belgium",
"       </td>",
"       <td>",
"        London",
"       </td>",
"       <td>",
"        Belgium",
"       </td>",
"       <td>",
"        Netherlands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Subpopulation",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        Adults",
"       </td>",
"       <td>",
"        AIDS",
"       </td>",
"       <td>",
"        Elderly",
"       </td>",
"       <td>",
"        Adults&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Case",
"definition*",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Number",
"of cases",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"7\" rowspan=\"1\">",
"        Diagnostic categories&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasms",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multisystem&bull;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"diagnosis",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 1: no diagnosis at time of hospital discharge; 2: temp &gt;101&deg;F (38.3 &deg;C), duration &gt;3 weeks, undiagnosed &gt;1 week; 3 = temp &gt;101.3&deg;F (38.5&deg;C), duration &gt;2 weeks, undiagnosed.",
"     <br>",
"      &bull; Includes collagen vascular disorders (eg, systemic lupus erythematosus, rheumatoid arthritis, and vasculitis), and granulomatous diseases (eg, sarcoidosis).",
"      <br>",
"       &Delta; Numbers represent percentages.",
"       <br>",
"        &loz; Immunocompromised excluded.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Alt, H, et al. JAMA 1930; 94:1457. Petersdorf, RG, et al. Medicine (Baltimore) 1961; 40:1. Vanderschueren, S, et al. Arch Intern Med 2003; 163:1033. Miller, RF, et al. Int J STD AIDS 1996; 7:170. Knockaert, DC, et al. Clin Infect Dis 1994; 18:601. Bleeker-Rovers, CP, et al. Medicine (Baltimore) 2007; 86:26.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8589=[""].join("\n");
var outline_f8_24_8589=null;
var title_f8_24_8590="Contents: Pulmonary, Critical Care, and Sleep Medicine";
var content_f8_24_8590=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Pulmonary, Critical Care, and Sleep Medicine",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pulmonary, Critical Care, and Sleep Medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?7/5/7263\">",
"         Asthma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/12/1231\">",
"         COPD",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/50/29485\">",
"         Critical care calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?24/45/25302\">",
"         Critical care medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/11/42174\">",
"         Critical care neurology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/2/18465\">",
"         Critical care obstetrics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/57/7056\">",
"         Interstitial lung disease",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?10/11/10430\">",
"         Interventional pulmonology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/57/15263\">",
"         Lung cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/55/22398\">",
"         Lung transplantation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/12/1230\">",
"         Neuromuscular and chest wall",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?21/20/21838\">",
"         Pleural disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/0/35853\">",
"         Pulmonary diagnostics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/25/43421\">",
"         Pulmonary imaging",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?6/2/6176\">",
"         Pulmonary infections",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/24/41357\">",
"         Pulmonology calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/17/1311\">",
"         Sleep disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/45/36574\">",
"         Tuberculosis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/34/559\">",
"         Venous and pulmonary vascular",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/63/31732\">",
"         What's new in pulmonary, critical care, and sleep medicine",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-6DF5E8BE9F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_24_8590=[""].join("\n");
var outline_f8_24_8590=null;
var title_f8_24_8591="Calcinosis and scleroderma";
var content_f8_24_8591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcinosis in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 263px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEHAYUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD551D/AI/JSD0AquMnBzVvUEDXk2OwFUiQuVNAClTuzu4p+AQNzc1CxP8ADzSrkj5z9KAHSINwA5qaOJRgmoO+anRsrz1FAD2SPFRiKMA/L1pWdRjHLUPkDpyaAHpErJjHSnKkQOWT261EsjrTgS3JoAnRYlYfJ8p96kWKPJO3rVYHmpVkwKAJtkY6JSjYP4RUJkzTS1AFjco6AUm/NQg08H060ASDGeRUypEy5ZeKrYIPvT9xA56UAP8AJhZuF4HvThBCOqn86jiQs/HJPSuj0bRXldTKpIPNAGRb2PmH5IWOelbFnoJYhplIX0rsLHRlQYjQZ+ldN4a8LvqsjKy4RevFAHF6Xo8UTDbGxFd74c8ITanKqrCyRd3Nd3pXgrTLNVkkxKR/D/kVvKshi8i1QQRDjAHNAFXStPsNAh8jTkMlwfvyZ4rdlnjsNO+1XH3uwqtplosZPmkFhzk1znirVRe38drG37qLqB3oAkuzLrciPb/KCeeK1DpfkWu7JbaOlS+FAs0DSlNrDpWrcssY+Zc0AedX0gvLC9g8zywg+4R9a+c/E06/bJkHVWI/U19DfFeSGy02W7s2EM7A5I79a+YNVmaSZnY53EkmgDPaTg5H41E3ByvU0sjkjGRtqM5xgcigBzHj3ozgDnioyMkcZpVDbulAEq8/MeR6UbsEleM0g6deaQDuTz6UAOEhHBFIXOacScckVCeTQBOshA64oMozxzVc49c0DNAE+/PWjzD2qGnAUAShz604PUIpw+lAE4kpQ5PSoQM1IoNAEnJppX6Umcd6aTQAEUU3NFAEd/kX030FVZFyCWq3qJA1CfPoKpMNpyTnPagCMg7xjp3pSccDpSZJc88UuAB70ACEhst92pAwPI4FRkZ5NLgk8dKAHA/NwM05m/OmgYoNACqSTk1KOlRggUpagB2eakUZqJDk1PkAUAGKUCm5zTkYA47UAOAx160qmjtgc+9SRxln+QZNADkHbvVq1tJJ+FXP4Vb0vR5JnDy5Cmu00jRxHgIvHrQBi6ToexQ7Ll/pXfeHdEluyqRRkt9K0/DHhi51W6WK3iJHdu1e3eHfC9poVpswrzsOT6UAcVo3g+OJAZhubuK67R9Ch08mW3AXP3lrS8gRudp5NWUxHExPQigClPAI23qPlNZ1643hAcZ9K0ZLtI4Cr9D61znmNJeMc5jXnNAF7ULiS201lj5lYda5bTrAST+ZICWzk5rZhvkup3jzkLwDSvCqRkowDd6ANG31CO0lWNVAUjnHFNv7nzNzI3Qetcrqtxi1fMg3LzkVxWrfEEWNnPbxktPggGgDK+MniRZozYg5ZcgkH614fcSbzuBJFa2tahJdXcsszEySMTz9axH4ycg59KABfnHXFKyDHJxSDIXGODSN8w3MRkdqAFCqR1ximEccUHnn9KXOfYUAJkd6UfMflHFNY46Cmqx3HGc0ASc5xTT6U5dzcDineXt69aAI+BR9akC0u0CgCMCnAUpIpM0AO4pc0zNGaAJQ2KXcTUQNPBoAdSGikoAKKKKAI9SUfbp+ewqiwz1qzqLFr+Y+uKr5zQAwg546UoFPxS9KAGgU7OKDSUABaiigCgAyaAM0E8cUDPrQA9GwcVKT8wFRDgjHT1qXtjFAACQ3NPxt60sEEkzqqjJPeuj0zw+8jr5nINAGPZWss7BUUkGut0fRAmCwBJ61uabpCQbQqgmuu0HwzeahIqW0LHOPmxxQBz+n6cQigLkk8CvT/BngW41Hy5bpfJtxyS3euv8ACvgmx0iNJdRIlmxnbnOK7D7UjARxAJGvQCgBNOsbTSbVYLGMKRwW7mpSpdiWPNKnKg96ZdXEVrEZJ3CKPWgCu6Im5mPIrI1DUwF2g8A1ia54wgZjHaAsPXrXNXWtbwcg560AbviHX4ntPKQFZR3rk21m6SExq4w3BPesm9vS7mRutZcl+oyxODQB1Ok6kILjBJwa17rWV2E5wPSvLJ9XMbl9wAFZ1/4pbySqN83egDrPFPiKKKOQxSckH5c/WvIdZvjNK7jlzUeqao0shctv9hXp3xp+GT6T4a0XxVo8G2zls4F1CGMcQylFHmDH8LHr7/XgA8UlJdsk5NROcDnrTgQcnvTCwOP50APQ/JnI+hoY5I45puOcg5o6sRggCgCRgCvBGfaotrnpT3VVA25NNJ7c0ARO2TtwR704HtjFPpKAHKxUcUu4nrTKM0AP3UmabmlFAC0ZoApwWgBlGKk20bRQAwU8UbRRQA4UUgFLQAUUUUAQ6iubyU+9VQOatah/x+zD0xmqyjNABQacRimGgAoFFLQAhphJqU8Dgc0wjjLUAJkjpUgX5cnoaaqHAAGc1ftLCWbrwooArKhJVUBIrXsNMeZhuXn0rW0nR8sMLlq9B8NeGZbl1ZIiW+lAHL6R4fOFO3Ga7/wz4Xe+mWNOAMZrqtO8F3Ji3EKGHb/Jrs/COkLagq42TdxQBm6J4NsLTa84Mh9P8murhaOxTZZwrGoHUDBq+LULkBfmqlcKdxTvQBnSXEssxJck571o6dksCxNU3twjbs81etXVRvPAUZJoAvanqUGl2ZnnYDHQeteWa9r1xq9wzu5WD+FRTfGGtHVb90ziGI8D1xXKT3RRTk/QUAWZ7gRtlQBVR7onOTWXc3pZ1B4XPJpbi5jCjy+eKAHahNsUHPymuU1jU/KBC+nao9Y1kiZkXtxXI6jfFmIznNAFi81RmBy59qyJruSQfLwaqsQSSaTIoAeSSSc19VXHxw0PUfAeq2ei6Jc3slhp6CW31EIkckZZYmPysxYAupI4OO4r5SBxXReALyC18VWcd+wWwvA9jdN2WKZTGzf8B3bvqooA55hySMAHsKNox0qfULSbT7+5srtClxbytDKh/hZSQR+YqvuoAcpHenZGKYDRmgAI9KaSe9OP1ppHvQAUhNIaSgBacKaKkWgBVSnhcUopaACiiigAoopCaAGscUmTSNTKAJ0Oepp+0Y61WFSqTQA/FFGaKAEvgrapcbhjgdKpvwxC9KuX+Dq9zjpharyDHK8kUAQ7WJpSu0ZpBnrn8KUk470AMNIvHWnLhjzVq30+W4kG1SEoArscYHP4VctdNluCDgkVvWeiDIyufc11el6KRjyFZ3PGAM0AcppuhM3GM11WkeHZJGCxxlyew5r0fwl8Pru7IkuEMUJ56c16hpPh3TtGRfKjV5R/ERQBwHg34cySKk14vloOfevSLTRYLBQtrGoAHWtaNi6DA+X0pWLZxQBVtlKScmtCW1WZBJH8sq9x3qr5RL+lXkBROtADrSdbhCjcSrwapXVv85dTzTbg/Zr6OYcB+oovLkKzY53CgDNeTMhHcVW8R3Elto0oiHzFeT6VeWJUUzykKi8kmuB8Z+Kkmtpba0wexagDj7i6XDMTk55NYV/eZyVPNR3t2EixnJzk1zOoamBkKaALV/qJU8tWPNrUyKwRgFPrWTeXwJILc1mSzmVuvFAFi8vJJpDtPJ6mqL5JySSalXAHFI3FAEGDRih39KaGJoAftpdopuSBTGY0Adb8Q/8ATL7T9d4I1izS5kI/57rmKbPuXjZvo4rk9wp89/czWFvZSys1tbu7xIQPkL7d2D152jj/ABNVhQBOCKXI9KgHucClMnYUASEikz7U0ZxSEn1oAUmkzTaBQA9ck1OgqFcCnhwKAJxS1B5tHmmgCekLCoDITSbqAJS/pUbMaaWpM+9AAc0AGj8ad+dACgGpFHvTAacpGelAEmPeipI03DpRQAt8B/adxng4FQPgphOvrVrUYidTuGBzkDii1s5HYcfKaAM8Lh+B81WYbGWYgkYFb1lpAL525Nb9horSPgISfQCgDmbDRlEwJGa6Wx0tg4UJknoBXc+G/Ad5eyK3l+XF3JGP6V6joHgnTNNIknAnmAzyOn6UAeaeGvAt/qW1vKMcR6k8V674e8KaXo0SkoJZv7xFbSg7QsKhE6YAq3BbhV55oATcxQBAAvYAVEYixwwq+sYwQOaVLZm5NADYECRqB1qZYQfmap4LcRjLH86WSRAeo/CgDOmbD5HSrH8A71HcAMp2Dmkhb5MHtQBT1kfukf8AuVi6jrMVqEd4sqeM10Fym8EN0auZ1qzaW2eNRkCgDmfF3ic3kP2e1Plx/wAWO9eZ6jdhFYZ4711WvWJ2tsJDCvNNbnlhLq+aAM3WNTAztPFcteX+77vLGotWuTJNhT9az1JQHHOaAFdt5ySc1JHUeAVGRjNKuV4oAsg4FQyNmlZvlqtI5PAHNADh8x46U/gVBuYDA6ijc0i8DkUASSShRjvUW5mPtSqd33zihgB0OaAEYnr1pC4owKAtADc+gpc07bSFaAE3H1ozSEVc1rTbjR9YvtMvQourKeS2lCnIDoxVsHuMg0AVc0oNMpcGgB4PvThioxThQA8Ypcim0UAKT7UmadS7aAGUY+tOKmkORQAoGO9OB96aD709cUAKDTlBJpBTl4PU0AWoEypzRTY5AB1ooA2DYF9UuGbJ4Fb+l6M87qqqST0GK1LLS2m1KQBOWxxivR9C0SOwZCUDyHpx0oAwtD8GqVD3J2DHQj/61drpGkafYFdkId/Wr0VlNPgsuAO1aMNkIxnHzUAXrSR3AXAVR2ArTh2jheves62UjAK81p26kEZ70AW41AA71djjJACjrRbwDG5+FHrUF9q8VudluN7eooAvhUhQtM4GKqS6tHnZAu73rFknmujmVj9KvWluqhQOtADp7maRfmJAp8GcZLE06UhSVxmktxldwGaAJi4PA/On+WCoxUUQ5Oatow28CgCnIcqUPUd6wdWkMKEqeT1rfnAQlj3rPubVHjYuM0Aeb6xEJCxIwTXlPje1cbvLXJ717dq1llX7HnFeba/pkpd3IyPpQB4JdwMJ2BBB71WKEHBPPbiu81HSQ07Hbg59K5+5s/KciROvfFAGI2QOetAJI+bir0tkeNnNQfZmUnOTQBCCB060q4AJYUFOenSlAyfmGBQBGyjG5T1pqjZkH7p71YaMfwcimMML1oAqsDnjpTgpqVTtPNGM8mgCKlp5X2o24oAaFJ6UpjPelJYCgEmgCMpium+KQ/4ub4u/7C95/wCjnrnGBHUV03xRX/i5fi04/wCYvd/+jnoA5X8KKeAewppJBoABmlApVJ9Kd+FADRSincelKFB6UAIKetAiJ6VIsLUAKBntQYwaesbDtTgCO1AFZoqbtxVz6io2CntQBCtLSlRSdKAHD3opM0UAfR/hfS/M1ovIMKMV6Xa6ciAyBOR0rB8PWflXrbkOciu+tLbdEQ3TFAGfFCHA2jFOSDdnA5FWPLKSFFHy+tWI4NoJPQ0AUYY/3mMc1p2oSP5pBgD1qOFB54B6VW1m7Abyozx3xQAmp6s058iA7U7mqMKrF945J9aqqGL5IwKmHLigC/G+1gdvFagYLEGPU9KzYE38davFD5YDHpQAi3KNkMKmglUISPu1TZQAfWltydjZ49qAL6SqenOaerqpwazYGaOTc3I9Ks7xIxZT0oAkvZMYFVXdWi5OKbds08gSPgih7UrFyeO9AHOauVc4T8a5vUrdJFKsv1ru7nSTdoWtxggc1yN/bSRysjDOPbrQB5d4i0lYLjzFHyGsO6sbaeEqUBPrXo+s2wnidSucCuWXT+cHjFAHnl7p7W7bNh2+tVzbqFI2ZzXps+lRzJhlB/CsKTRhHMy4+X6UAcI1gpBwpBqBrIHANegyaRGUIUc1nPpTBj8nNAHGzad3GR7VXewKgEdTXdLoxchcZapZPCd6Yy627bR7UAeeNbOr/KuRTGicEBhx9K6u4sWgbbJGQfpVSW0DcAYNAHOpCWPIIH0p5tWJ+UVui1BOAMe9KLcB8nkCgDEWyb+LrT1sHJz2reFuMkkYHYU4W3QKpOaAOv8A2fLXQ5PiDDY+I9Ns7+C9iaKEXcQkVJR8w4PHIBHTqRXWfta22j2d/pNrpWl2FvqdwZLy8uIYFSSQMcLuIGWyd5JPpXldibjT9Stry1JSe3kWWNx/CynIP5it74jeIJfGXiy61V4zGkgRI4jzsVVAx+eT+NAHlf2aYnLHA+lNkgZOxI9a6me0wcBefSqb2xV/mWgDBWPnrT1T8a1ZbYc4Wo/spXjFAFJUP4VNGme1XYrYGMnIBHb1pY4Mc4oAgVBTsYqwYsDrioniO0mgCBpAKiab0pzx5XvmoWjKjnigAMhppbNK0ZAyRTDxxQApopmTnGKcMk0ALRShTRQB9629srTHEYB9cVow+ZE3lSLwehqeEJGx+WrgKsASM0AUfIABJFQNliQvQVslQy9KrywrtO0detAHPXN2LcFFBLn9KyyGebdJnFdd/Z0JOSuSe5qneaURlohn2oAw32lQFGTSCI5BBqaa2njBxGaW1V1OGUmgC9bxhYdy/eoDuwIbINSQk/d2nFSvHxwOaAKrA7enPagDC7Tw1W44iT06VFJGzvnbzQBWZyn3hTrWXDkngelPeB26oSKdbWUzy5KkLQBHC/8ApRJB5rTkjZ4cAcHrU0NiAclRkVbjiwhBFAGREzQIYwOTUNxpsUkDu6jce9bYtUzk805oEIwRx6UAeUX+lsl05EZYegrDHhe/up2aKEhCfSva5ILaM/6sE+4qlNdDeURVRfUDFAHneleBJN+b+QIO2al1L4eNgvb4dfUV1khkWUs7Mw+tW2vGEAIcj8aAPJ7jwU8UbEff9MVy97pjWkjJMpVu2RXvYuo5wBMq/UCsfxJoNrqtsVVAsnZhQBxXgDwrCj/2nqCbgp+RD3rrtU1HDFIreBUPGNnatPw9YeTo32GXl0HDVzmpI8N08bA8Z5oA53WPCula67FNttP3J6E1574l8AalpzM8ds8kA58xehr0tm8pywz1rX03XWQAMBIndJPmoA+cxpNxG5LwuB7iniyIORGw+or6e/4kuox/6RZxjPXauKaPDnhxlysGB70AfNAtHVhmM5PtWvbeGL2ZFlMLCM85xX0GnhnRVGRbqVHQkVfh061XCxRrsHYjigDxXSPBccqhpyMnopFWbn4bwyB5I51hVRklhXsc+mQO42KqH2pxtYwpiwpOOcjrQB8t3nh+6N88FohnjU48xRxUNx4V1ONd0tlKE/vHvX0XrNpbhDHBHDG/fauK5ue7a2jaKQB/TdyKAPn66sZLcnzImGa3NN8Kxvp/2y9lAVvux966/XEiuywESlj3A6VFJamPSlQnPp7CgDgrvQLlN0lnGZE7KOorKltzEdswMcn90135MlugZGIA681q6deWVymy+t4HX12fN+dAHlbKGTk8D2qIxMy52nFewXPhzRNSjbyh5f44xWO/gS2JPlXOV9N1AHmrQZHYH0qtcWpA5GB716ZdeFLOwj5LM/oTzVOe1tJ/3Ji2Hpk0AeZzLtIBBHpTWw6DpxXe/wBhCzEyCMShhw5GQKy18LSXas9tIkb55Vu/0oA5QoBjsaVUIPPFXb+ye0uRHNG6sp6noag2bj8p5oAWHIX7uaKsLBcRjiylkB75orWNOMldzS+//IVz9AooMFt3IqwkQCjFKqMCeafsIxzWQwPC4PWm4FOZD1JqGUHPBoAazbW68U5X54NQhCW+Y09Y9p4NAFkKjDlQaBbREbgg/Kogh9alAJ70ABt4h/CKPs8fUKKftPc0FTjrQALEig/KOab5MeeBSkY70AcdaAEKIvRRinE4HAFMCZOM0oHOM0AOBzQBxTAp3HmjnHJoAcenFQyuR0pwDc80yRTxk0AVpVLKdxFZ9wiIM55rTljzznisq+UbTzQBn3FxhDuxVRZGniIB71DOjtJtY8VPYRESbe1ABbq+QjDp3rctYjsAOCKzQjC4KgE1q2odFO7GKAIpz5FyhA4NZ+rwxrK0rqDkcVpT7ZZVXOSKxNcudsrKpBI4xQBx2oRSGV324U9AKoJE6hmPAFadzKrSHe5Htms65kLAKmT7CgB9nKw3Nu247GtvTbzzCA3SsS2smnGSGz2ArY0zTJ1ILqQlAHSxupQDJqRDtbKE8VSht2Q8E/jVgRNw28fSgC55h67uahldlOcioZZEQctmm+fGyfOTg+lAFDUHSRiQDvArnNWi86AsV+YccV0d48acxA5/2hWNJGZlk8oMSeuBwKAOIkCwLJvjOSauXtoDpUTqP4aS+t/s0rGeVSD0FVL3UtulMkhK8/KB6UAc1doA53K/XoOlSW8SOMxqfepImW6cBdwz3P8AWrcUVlaPuutQt0XuA2KAEgc7NkZAI61oxPPHGrRbAfVqaviLw9aR/u3Ejdz61H/wlmiy5ywQds9KAGarNvRWmKvL6p0rmJlla7fKjHatHUtRtppN9tMjg9AvasuR44908l5HgfwBuaANSOMSacGkfD59azo42DsUkVc9x2p9jeQTWLSeaoCk/KetUJtdtoY3KJmT6cUAQ6i8ixmGVIph1DkZNZKp5jrGLcYJxuApJtcmkRiY0A+ldn8PLNdSiaa42eWvOB1zQBYtdMitLaJZ9zMyhhg9BRXdDT7ZlHnxv/s49KKAPoFjz0pw5FMJy3FPHAoARxuGKjKgEE1YQZU0x1OeOlAFYqC/FPWP5uelSCMFs0/Zg80AM28UoXinEhfvcCqs19FGMDk0AWjnFBBxWNcaq44UCqcuozkZBxQB0mM03PPBrlH1K5xndVdtWnAI3c0Adnle55pvmIG5IzXCtqVznd5lRS6ncZBD5oA73zowTlwKb9oix98fnXAPfSuCTIRVV7+VQQHNAHov2uAHmRfzqGXUrZR80i/nXmct84P+tYk1Uur35fvtmgD02TWbFSd0o/Os661/St2HlH515jLcknLE1j3cqksMc0Aesyarpk7fupUz9aWzvLYzbUbPvXipd1H7tmU+1OXV721TCScdM0Aeyat4p0/TGIOHf0Fcxq3xBLwMLWIjIPb/AOtXms1+ZCXkYu56k1QudTWNSu/8qAPafCOvwzafI08ym6bopNZuo3UzyO3cmvGf7RkicSQymNxyCvep38W6h5ZV3UgjqTQB6TPqFhZrvvp41PoTzXK6p8SdKtJmitbOd2HRinB/SvNdSvnuLkyXDGYejdBWbdXhLccJQB6JN8UtSYkWlrbRjtuGD/Ks64+J/iJRkNB9Af8A61cD5wYEluaqyzA9MUAeip8TfERQ5aEE+/8A9amyfEjxCE+Z4fwP/wBavOVuB90mka6CttBytAHoifETV3/17jn+6f8A61MufHWrTAKlwUX1B5/lXnhvADwKZ9rOTt5oA76PxxrELEC48w+rn/61Jc+PNZlG3zhCvcxHr+lcAbljkHHNM81+zH6dqAOpuNburk5lvJT3GTVyfxVPcWqQXAX5BgMvU1xIZiTnG4+lL5jKMHmgDoLvW7l12RTvGP8AYPNZ80/m/wCsJc/7VZwbJyODTt7E8DJ9qALaPk4UAfWllcEYbGaqKSTycGnIDzk0AWYbl4M+WxU+gqYS7xuY8+pqpkY+brUiFWGGJx6UAXEmKrtBOO2KcHLDoM+9UGcIcIWz+lPSRtmGI+ooAtvzgMR+HStLQ9XutIlLwNmP+72rFWQE4HWpY2Ibj8aAOzufiFqIZeB0/wA9qK46+JDrhQciigD9C1GAc05vu00d6incjbjrQBZiPynNLu29elRRHPI/GlmUiI80AOJz04pGZtvHJqurtxu6VIZcfSgClePJnDk4rMmIC8H8a3ZNrrhwDms28sHIPlflQBkSyAHk1A9yOQaS+imgXLRknPpWZLKcYwQaALMsy7TzkGs2W4+cjNRmYtlQahlj3AFT8woAmkuQBxzVWa4xkg4FV5txQkE5FRld6gk/hQBI14cEDiqrXbknmiVlIIHaqdwSFBQ0ASmQsc5wajmkAGSeapNM2CBUEr/LuyTQBZlmXB55rPndWOcfNULk53etRs+DQAy4lCA+p9Ky7i5OMMK1JImkGQh/Ks+4t8/fBA+lAGVNLuyqtjNZ81uwUkkt3zWtJbokn3QVPemOisNqrkdhQBz0244VMhvWq1yrIvztkmvQbLwPqepWhmhtWVexIIzWR4i8E6lplsJ5omJxyMHigDgppdq4UkmqVw/HI61oTwsHYMNuOxqhcRkjjt3oAzXJLEA4qEvgcn8quSW2PmPFUpYv7nXvQAgkXg9KHcA7hz7VGsfzYbg1IsB3e1AC7tw9CaRSRnuKebYk5JNBt27ZFAEZ2jlm5pN5zjsfWlaA9hz60uxgPnXJHrQA4EKOoxS7t3rTBGoBOOD2o2uAMnigB+QHHP4UqvtOV4qMoSfkpeRxjcRQBMcMScYNLv4GAM+tVy7B/lORUnOKAJemGzk09ZBj0quGx7U8LuJwaAJ3f5RzSmQDA2qPcVCvPXpQAO/5UAWiy7hjOfWrKnavqfWqoZAgGMnt7VMmQuWwaAH3cxVlzzxRUV3guvHaigD9D3ciTAGRTJMtIPSpHIBNA2kDsaAH8Jjb360sv3aQsM80H5uaAKwDbSDnHapVUtHtbtUpz6UKuT/SgCrJny+OopyOxAyOaslAaQJg9KAIZgj43oCPpVOTSbOZyWjBzWg/TkZphUigDEl8OWjOdgxVX/hFVIYq+PSujIIOaFfGfSgDkZvCLMpKyYz2qgfBdwxO2Qiu8Zj1xTfPC8d6APPJ/Bl6oYJzWZP4P1QHKxkivVhdHPWkN6RkEj8qAPGpvCmrhiBAf1qP/hENXkYL5BA/GvZG1Lk8j8hUM2oSEZUqB9BQB5ZbfDvUrj77eX+NX4fh9DajdqE+4joBzXXX9+5PMuPpWJPfFpOWOPrQBCnh23WImOIHHSue1nw8gQmSLbk9hXU2WsbZtmePWtCe5W5ZYyiuD1NAHi+oeHpYFLR5ZDzUvgHSI77WHN0mRD91COuK9avdKtHTcgCn0xWBb6cum3zXkK55w1ADr/xXNZsbeNRAE4ChRWfc6+t4g+1BZd3UMBzT/GGnfaGiu7YcNya4rVmZZgMlMdxQBc1zwBp3iFHn0d1jusEmLoM/WvJvEHhXVNIu2iubV8KeoUkfnXpWnalNb3AYu2F7111r4livY/I1KCOeHGOQKAPmiWIruR0OfpVFrc4OBX09deFPDOqAtBbpC7c8Y/wrMuPhZpcqHy5ACfQf/WoA+bxb5OQOKn+yAKCa95b4UWCKR52W/wB3/wCtVa4+E8MgGy7Ix/Dt/wDrUAeJCLJ+YZ9Kk8gMMYH1r2aT4SosQ2Xh3/7v/wBas0fCq5Zyvmnj26/pQB5OLfIOOMUhsxJk969cHwnlTmW7MS98Ln+lSxeDNOsZFjmUTk8bzx/SgDxlrUIhGd/1qLywF+4DXrOueA4EcyWkmA3QY/8ArVwt3oc9rqMdvMvyswOfUUAc6sLkMSrhfXbxTBGWyAMEV6Tq0UVtbwwRxL5QHzLjrWE2kWuoSbrVvIPcUAch5eASKCGXHvXRXnh+9t8sI/MjH8QrIkhwxV0ZWHqKAKrKDwRQOBxUwQ5weKaUIY8YoAEAHJqZQAOR+NRxL/d5apiDt+bIPpigBpZc9KlTaeFJqDaN2W4pQwBODu96AH3hYOoHPFFVr6QrIu4/w0UAfo/InJqMgjFODfOc06QgR5oAikOEBPWpYZAyc1C43Y9KXIVsDpQBM0hHOOKj+0oDknFBbIwelV54UkUnoaALD30CY3MOahOrW2fvVlXFi59SKzZYWU45BoA6c6zZ5wzUHVbF8L5gzXKPFlNp/Oqc1uVwVz+dAHeLc20g+WVaX92ekin8a87kWYDCSMPxqoLm9gBYTNjtyaAPTWjbsQRUTx4OcZrzuHxPqURwGJAq7b+NZV/4+EyPrQB2LAg9KrzKW9qxYfG9g+BIu3PXnpV6LxHpUo5nUZ9x/jQA/AjB45rJvrpwdi8DvW19rsJhujnT8xWfcWcEkpdZkYemRQBgTh929mOys+VmZ8oOK3L6PHyhcgehqKGC3GGyN1AGXY27mRiwJ9KvxsYDyTnNaCohP7sDHc1VuIsMSV49aALazGcLxyKbNFvilXb1qlDOUPbHbmrEd8hhdQwZy3Y0ANvrcDSkWQc44rzvWbZBcMNu7Peu28QaiohSGJhlRzzXEX8wmaRlbEp7UAYkjLGCrJnHepbOcFSypj05p62rywlj971qO3028MufKLDsRxQBq6XqXln97z7V0lpePIu6MkKawdO0G4MgaRN2feugtbJ4mVVIC+lAEwuJcHaetNSadWwRvB/CrBsy54XH40klqwwCcH1oAZDJMrltuB6Zqybkr97GDVeRZIyAAcVGd7EqENAFW+vtrEM2Y+9Ys5tp9xh7VsTabHL/AK9sZPSqZ0aKGRtsg2sOlAHNXc8n+rJynaufu9LM2oQyPyQK39YtXgkI+6o6VU0xhJdbWIZjyBQBg6vbMGfPK+lc9FAySnamQPfFdhr7eW7K46VzEsh3jnefbigDR08tGNrfdPUEZrUOh2OqxklFV/pVDS5SWVWTg9faukjRIxmLg/3hQByN/wDD1zJvtWwvp/kVRl8AXRcb5flHt/8AWr0dr50hAVSx9ao3l7IU4zmgDgpfDC2a8/M685qhdWkLxkNhXFdZq91cS/6yEj0bNclcsxnJc/d5oAxI7bZKxA3IO1Q3dqQN8Ayp/Stxo1WFmHAPeqCymPJyD7YoAw79m3pxnC0VoanHHNKrMnO3tRQB+hxkG/ipJGGwZ5qmgzITnNTs42gg9KAFkYIvIqAyg0+U70OTwaoyxtH8wPFAF3eO5p6uG47VnpLu+tTxZL8nFAFwso6jIqpdWkc4ynDVZAz16UMq447UAc9eWs0LAhSw9qpyN2YYrrRgr84yKhmsLeZcbQD60AcjPGNu5aybhGY7SPlruZtDjI+Q1k3ugTbSYyKAOFvYWRj1rMkYgnPSut1DSryJDuiZse1c3d20qk+ZEwH0oAxLmTGcn8qpO3fe4/GrlztRjkHPpVVlTqT+FADPtVwo+S4dR9TUTazqER+S8YY9SaSfyiwApotFkPyjrQBpWvjTULdNpPmt64q9b+KEuP8AWPslNcxNYlG5BA9ap3EQT7vX1FAHp0euCC2LCdc4znNZV544VYiscgdu4xXnMk8oGGd9o96rXrXgi3xW7FfXFAHYXPja4ZCFjYZ75qj4d8dNYam/9oNujk6E9q84u9RuI2YOCvsaoSXLSqd55oA9svdWs5Gkn+1qyycjmsKbxVpmlFmnlDbunPWvJWndSCZZCP7u6oZmEjEk7j6NzQB6PffE9YDiws2kHqKzp/ixq+QYIPJ/3hmvPZZgmcDn1FV5JS/IOfU0AejD4t6+ASWU/RaRPjFra8PCW+n/AOuvN1YbDg5aq5ct91s+vtQB6/H8adVTG+1dvp/+utSH43Tqg82wkb1Of/r14WJsHdnOKBLuOWbFAH0InxqilIMloyZ9f/11eh+L2nsp3gZ/l+tfNwuMjPXHFSJMQOQOfagD6PT4q6K5/eyLGD3P/wCulfx3pMjiX7dH5OPvV83/AGj5sbAPqOtKtwd3IOP0oA911fxl4enBdb1bh/7qkiuc0nxRDcapJKx8iNQQgJ615eZAcsqAD1xTvtB2jBOfagD0a71tJtQd3JYN2z1pUuLJnDvqEMI7oRkivN2uJT1c59c1G0zEgFiffNAHrsWv6JaH57pHI7ir8PjjQlACN+ZrxIOWb5lyBUpcIfuj6UAe2nxroshyJlX60DxPozqfJuo1b35rxMPgfKAQfalycZHB9KAPT9Wv1di1tIJAfQ1zkl5H5zJMvLcAZrl47qYgAO4H1oZ3b+I59TQB0t1cgoIwuFFVFWHG53Cn0NY5nkxtJJ/GlQ7sFyc0AX717YOu6QE4orI1DiVeR0ooA/Q0XPBUdTT2uAECk81x8WtYmcEc9qtJdu7byeO1AHSC6Axk8ClNwJVIrnXujIiqpwR1zUlrdFGBHNAGldTrb4J6UxNctoiMndSsI7mLa3Q9a5XWNImt5Ge3yydcUAdjF4itXYg8CrsOpWcvSUAntmvKROSwDcEdalS8aN+CeKAPXAUcfIwNDFgM46V5lBrFxAQ3mtz0Ga1bbxdNGQJl3L3wKAO2EpxmnLKeOa5228UWU+Ff5Ca17eeCdQYZQRQBdaRGGJFU/hVae3s5gRLCpz7Ujo4GcZqs7uM5HFAFK+0PRpm3NCFJ9hWBf+DNEky5m2e2a17t2cNg8VzGoTSrK3mHKUAR/wBheH7Mj5vMI96RLbTHnxGgCis66GRuxVYGSNMJ99u9AGtrHhdZojNp5WRMcqOorh9X0OWONmiQq46g16L4dvHiYB2YHuO1Ta/CsrCQIBk/Nj0oA8k8IaTDqF7JcXZ/cwnBX1IrpdU1SzjQ28NsgjHTI5rR0LSY7J76AjJlBlGO2a4jWIZY5JnOdqttoAy9b8O2utIzWpEc4GQp/irzrUrGawmMNxGyuPXvXoQkZAsiyFWHIwatsbHXoPs+rKsU3SOUcfmaAPI2AxyOaqyZ3HqK7jxD4E1GwBltcXEPUMvPFcdd2tzEMSx4I9aAMeYEv61E6sWwMqaumM5BPB9KjkX58N94dKAK7Bt5G0jHU1GYjwAcfTvVsglSOc0m1R8uetAFZYgM8c0pRViz1b0qcjPIpsiscDAPPagCntKsMjr6U9nIO3Gff0qTac1GY3U5xwfWgByDJ5Iz607hch6avzcYOaey5UhiPb1oAOAvyknNMU8ENxSqHZMY6GiQHaBwMetADl4bn86bhSfSkBPB5/GpCoODg/40AKCcAdBShecufl9O9Az1YEAUoUnkcj0oAVGw2F6elOL/AOyfamoNp+YZHbFSEY5x07UAKMkZHSlHTBoBITa3T2pSpAHIOaADHNKvt1NIAR19acqnkgH60AM1BF8xP92ii+LF0xj7tFAH13EFN3ISTgYrTS5OzaO3SiigB0c+VJHWpbeb+7n8aKKANS2usSDHpWilysnDDjvRRQBQ1fw9Dex+ba/u3rir20msZykjK2PSiigCm9x82GzmkknIX2oooAPPURFiDkVJBrE9uyvDIwX0zRRQBsWfja7gIV8OB61v2Xjq3mAE8ByeuBRRQBqJfWWpKRCjoT61i6paFCxJBHpRRQBlyxrJEMDkdagaNJQH5BHFFFADrcNG+Vxit62P2iAK4GWOKKKAIruzWC6eZe0W2vNfEiOI5RxtZt1FFAHIbC0RL444GKgkRQF3c5HGe1FFAGpp2o3toixmTzIzxtc8VokWF7N5V1apvbuooooAjuvAFhcIXUbfT/Oa5+6+GcTvvik5Hr/+uiigDA1TwFPbQySpLGVHr/8Arrk7nR5YZQrlTzRRQBE9gVABIp8OlyTHIYACiigCC4054jnI61VMJ3EMcjHSiigCL7OwG3I2+vehbYr0IPbmiigB4gK9+aT7Pk5Jzk0UUAK1qI2G45pwixkg8elFFADtg6N+lNZdpoooATC7wBnmlKjJOeRRRQBIpjUE8knrmmxyIrHgkUUUAOcxDld3rzSrPEFOQ34UUUARXs1uJF3+YOP4RmiiirjUSVnFP7/8wtc//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph showing calcium deposits in the thumb and index finger of patient with systemic sclerosis (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_24_8591=[""].join("\n");
var outline_f8_24_8591=null;
